Combination of Olfactory Ensheathing Cells	1
Combination	1
Olfactory Ensheathing Cells	16
Local Versus Systemic cAMP Treatment	49
a Cervical Rubrospinal Tract	92
Injury The failure of CNS axons to regenerate following traumatic injury	121
Injury	121
The failure of CNS axons	129
The failure	129
CNS axons	144
traumatic injury	178
part	205
a growth-inhibitory environment in CNS	213
a growth-inhibitory environment	213
CNS	248
a weak intrinsic neuronal growth response	263
Olfactory ensheathing cell -LRB- OECs -RRB- transplants	306
Olfactory ensheathing cell	306
OECs	334
a favorable environment	381
axonal regeneration , remyelination , and functional recovery	415
axonal regeneration	415
remyelination	436
functional recovery	455
spinal cord injury	481
our previous experiments	513
OEC transplants	539
regeneration of rubrospinal axons	573
regeneration	573
rubrospinal axons	589
the site of a dorsolateral funiculus crush in rats	626
the site	626
a dorsolateral funiculus crush in rats	638
a dorsolateral funiculus crush	638
rats	672
Rubrospinal neurons	678
massive cell atrophy and limited expression of regeneration-associated genes	706
massive cell atrophy and limited expression	706
regeneration-associated genes	753
axotomy	789
the same injury model	804
we	827
the hypothesis	837
treatment	857
the red nucleus with cAMP	870
the red nucleus	870
cAMP	891
the intrinsic growth response	916
other neurons	949
rubrospinal regeneration in combination	977
rubrospinal regeneration	977
combination	1005
OEC transplants	1022
addition	1042
we	1052
a systemic increase of cAMP using the phosphodiesterase inhibitor rolipram	1064
a systemic increase	1064
cAMP using the phosphodiesterase inhibitor rolipram	1087
cAMP	1087
the phosphodiesterase inhibitor rolipram	1098
OECs	1140
cavity formation	1155
astrocytic hypertrophy and the retraction of the axotomized rubrospinal axons	1184
astrocytic hypertrophy	1184
the retraction of the axotomized rubrospinal axons	1211
the retraction	1211
the axotomized rubrospinal axons	1229
the overall lesion size	1284
OEC transplantation	1309
the thresholds	1337
thermal sensitivity of both forepaws	1356
thermal sensitivity	1356
both forepaws	1379
None of our treatments , alone or in combination ,	1394
None	1394
our treatments	1402
combination	1430
rubrospinal regeneration	1452
the lesion site	1485
the systemic elevation of cAMP with rolipram	1511
the systemic elevation	1511
cAMP with rolipram	1537
cAMP	1537
rolipram	1547
greater numbers of OECs and axonal density	1568
greater numbers	1568
OECs and axonal density	1587
OECs	1587
axonal density	1596
the graft	1618
motor performance	1641
a cylinder test in conjunction	1662
a cylinder test	1662
conjunction	1681
astrocytic hypertrophy	1744
Axons	1769
spinal cord injury in higher vertebrates	1814
spinal cord injury	1814
higher vertebrates	1836
This inability	1856
a weak neuronal response	1892
axotomy -LRB- Plunet et al. , 2002 ; Filbin , 2003 -RRB-	1920
axotomy	1920
Plunet et al. , 2002 ; Filbin , 2003	1929
Plunet	1929
et al. , 2002 ; Filbin , 2003	1936
et al. , 2002	1936
et al.	1936
2002	1944
Filbin , 2003	1950
Filbin	1950
2003	1958
the presence of axon growth inhibitors associated with myelin	1975
the presence	1975
axon growth inhibitors associated with myelin	1991
axon growth inhibitors	1991
the astroglial scar	2046
Bradbury and McMahon , 2006 ; Harel and Strittmatter , 2006 ; Yiu and He , 2006	2067
Bradbury and McMahon	2067
2006 ; Harel and Strittmatter , 2006 ; Yiu and He	2089
2006	2089
Harel and Strittmatter , 2006 ; Yiu and He	2095
Harel and Strittmatter	2095
2006	2119
Yiu	2125
He	2133
2006	2137
this broad spectrum of obstacles	2150
this broad spectrum	2150
obstacles	2173
it	2184
a wide variety of strategies	2210
a wide variety	2210
strategies	2228
some axonal regeneration	2268
Aguayo	2294
et al. , 1981	2301
et al.	2301
1981	2309
Richardson et al. , 1984	2315
Richardson	2315
et al. , 1984	2326
et al.	2326
1984	2334
Li et al. , 1997	2340
Li	2340
et al. , 1997	2343
et al.	2343
1997	2351
Rapalino et al. , 1998	2357
Rapalino	2357
et al. , 1998	2366
et al.	2366
1998	2374
Liu et al. , 1999	2380
Liu	2380
et al. , 1999	2384
et al.	2384
1999	2392
Raineteau et al. , 2001	2398
Raineteau	2398
et al. , 2001	2408
et al.	2408
2001	2416
Qiu et al. , 2002	2422
Qiu	2422
et al. , 2002	2426
et al.	2426
2002	2434
Bradbury et al. , 2002	2440
Bradbury	2440
et al. , 2002	2449
et al.	2449
2002	2457
Dergham et al. , 2002	2463
Dergham	2463
et al. , 2002	2471
et al.	2471
2002	2479
Fournier et al. , 2003	2485
Fournier	2485
et al. , 2003	2494
et al.	2494
2003	2502
Rossignol et al. , 2007	2508
Rossignol	2508
et al. , 2007	2518
et al.	2518
2007	2526
the transplantation	2543
olfactory ensheathing cells	2566
OECs	2595
the olfactory bulb	2614
Li	2634
et al. , 1997 ; Ramon-Cueto et al.	2637
et al. , 1997	2637
et al.	2637
1997	2645
Ramon-Cueto et al.	2651
Ramon-Cueto	2651
et al.	2663
1998 , 2000 ; Keyvan-Fouladi et al. , 2003 ; Sasaki et al.	2671
1998 , 2000	2671
1998	2671
2000	2677
Keyvan-Fouladi et al. , 2003	2683
Keyvan-Fouladi	2683
et al. , 2003	2698
et al.	2698
2003	2706
Sasaki et al.	2712
Sasaki	2712
et al.	2719
2004 , 2006a	2727
2004	2727
2006a	2733
the optimal OEC purity	2750
tissue source	2774
age	2789
species of donor animal , and culture conditions	2797
species of donor animal	2797
species	2797
donor animal	2808
culture conditions	2826
reviews	2880
Harvey	2892
et al. , 2006	2899
et al.	2899
2006	2907
Barnett and Riddell , 2007	2913
Barnett and Riddell	2913
2007	2934
Franssen et al. , 2007	2940
Franssen	2940
et al. , 2007	2949
et al.	2949
2007	2957
Richter and Roskams , 2008	2963
Richter and Roskams	2963
2008	2984
example	2995
the efficacy of OECs	3004
the efficacy	3004
OECs	3020
changes	3025
the culture methods	3038
the number	3067
passages and tissue source	3081
Richter et al. , 2005 ; Au et al. , 2007	3109
Richter	3109
et al. , 2005 ; Au et al. , 2007	3117
et al. , 2005	3117
et al.	3117
2005	3125
Au et al. , 2007	3131
Au	3131
et al. , 2007	3134
et al.	3134
2007	3142
their greater accessibility	3160
OECs derived from nasal mucosa	3189
OECs	3189
nasal mucosa	3207
the favored source	3229
OECs	3251
autologous transplantation in humans -LRB- Lu et al. , 2001 , 2002 -RRB-	3260
autologous transplantation	3260
humans -LRB- Lu et al. , 2001 , 2002 -RRB-	3290
humans	3290
Lu	3298
et al. , 2001 , 2002	3301
et al.	3301
2001	3309
2002	3315
We	3322
lamina	3350
OECs	3372
several properties	3383
those of OECs derived from the olfactory bulb	3413
those	3413
OECs derived from the olfactory bulb	3422
OECs	3422
the olfactory bulb	3440
distinct differences	3475
transplantation	3513
the injured rat spinal cord	3534
Au and Roskams , 2003 ; Ramer et al. , 2004a ; Richter et al. , 2005	3563
Au and Roskams	3563
Au	3563
Roskams	3570
2003 ; Ramer et al.	3579
2003	3579
Ramer et al.	3585
Ramer	3585
et al.	3591
2004a ; Richter et al. , 2005	3599
2004a	3599
Richter et al. , 2005	3606
Richter	3606
et al. , 2005	3614
et al.	3614
2005	3622
rat rubrospinal axons	3644
OEC transplants	3694
the adult olfactory bulb	3723
the nasal mucosa	3764
newborn mice	3784
Ruitenberg et al. , 2003 ; Ramer et al. , 2004a ; Bretzner et al. , 2008	3798
Ruitenberg	3798
et al. , 2003 ; Ramer et al. , 2004a ; Bretzner et al. , 2008	3809
et al. , 2003	3809
et al.	3809
2003	3817
Ramer et al. , 2004a	3823
Ramer	3823
et al. , 2004a	3829
et al.	3829
2004a	3837
Bretzner et al. , 2008	3844
Bretzner	3844
et al. , 2008	3853
et al.	3853
2008	3861
We	3868
this failure	3889
part	3918
a weakness	3926
the intrinsic cell body response	3940
rubrospinal neurons -LRB- Tetzlaff et al. , 1991 ; Jenkins et al. , 1993 -RRB-	3976
rubrospinal neurons	3976
Tetzlaff	3997
et al. , 1991 ; Jenkins et al. , 1993	4006
et al.	4006
1991 ; Jenkins et al.	4014
1991	4014
Jenkins et al.	4020
Jenkins	4020
et al.	4028
1993	4036
such weakness	4047
other neurons of the central nervous system or dorsal root ganglions	4081
other neurons	4081
the central nervous system or dorsal root ganglions	4098
injury of their central axons -LRB- for review see Plunet et al. , 2002 -RRB-	4156
injury	4156
their central axons	4166
review	4191
Plunet	4202
et al. , 2002	4209
et al.	4209
2002	4217
Cell body treatment of the red nucleus with BDNF	4224
Cell body treatment	4224
the red nucleus with BDNF	4247
the red nucleus	4247
BDNF	4268
atrophy	4283
rubrospinal neurons , stimulated expression of regeneration-associated genes ,	4294
rubrospinal neurons	4294
expression of regeneration-associated genes	4326
expression	4326
regeneration-associated genes	4340
regeneration of rubrospinal axons	4384
regeneration	4384
rubrospinal axons	4400
peripheral nerve grafts	4423
a cervical spinal cord injury -LRB- Kobayashi et al. , 1997 -RRB-	4453
a cervical spinal cord injury	4453
Kobayashi	4484
et al. , 1997	4494
et al.	4494
1997	4502
this treatment	4519
1 year	4548
injury -LRB- Kwon et al. , 2002 -RRB-	4561
injury	4561
Kwon	4569
et al. , 2002	4574
et al.	4574
2002	4582
Treatment of dorsal root ganglions with brain-derived neurotrophic factor	4589
Treatment	4589
dorsal root ganglions with brain-derived neurotrophic factor	4602
dorsal root ganglions	4602
brain-derived neurotrophic factor	4629
BDNF	4664
the intracellular cAMP concentration -LRB- Cai et al. , 1999 -RRB-	4696
the intracellular cAMP concentration	4696
Cai	4734
et al. , 1999	4738
et al.	4738
1999	4746
pretreatment of these cells	4757
pretreatment	4757
these cells	4773
cAMP also enhanced their neurite outgrowth in vitro	4790
cAMP	4790
their neurite outgrowth	4809
Cai et al. , 1999 ; Neumann et al. , 2002 ; Qiu et al. , 2002	4843
Cai	4843
et al. , 1999 ; Neumann et al. , 2002 ; Qiu et al. , 2002	4847
et al. , 1999	4847
et al.	4847
1999	4855
Neumann et al. , 2002	4861
Neumann	4861
et al. , 2002	4869
et al.	4869
2002	4877
Qiu et al. , 2002	4883
Qiu	4883
et al. , 2002	4887
et al.	4887
2002	4895
vivo -LRB- Qiu et al. , 2002 -RRB- and their regeneration	4915
vivo -LRB- Qiu et al. , 2002 -RRB-	4915
vivo	4915
Qiu	4921
et al. , 2002	4925
et al.	4925
2002	4933
their regeneration	4943
cellular transplants	4970
the injured dorsal column -LRB- Lu et al. , 2004 -RRB-	4994
the injured dorsal column	4994
Lu	5021
et al. , 2004	5024
et al.	5024
2004	5032
acute systemic elevation of cAMP	5049
acute systemic elevation	5049
cAMP	5077
the inhibitory environment of the injured spinal cord	5095
the inhibitory environment	5095
the injured spinal cord	5125
some functional recovery	5162
cell transplantation -LRB- Nikulina et al. , 2004 ; Pearse et al. , 2004 -RRB-	5206
cell transplantation	5206
Nikulina	5228
et al. , 2004 ; Pearse et al. , 2004	5237
et al.	5237
2004 ; Pearse et al.	5245
2004	5245
Pearse et al.	5251
Pearse	5251
et al.	5258
2004	5266
we	5278
rubrospinal tract axons	5292
we	5325
the past 2 decades	5344
axonal regeneration	5379
part	5405
a weakness of the intrinsic cell body response of rubrospinal tract neurons	5417
a weakness	5417
the intrinsic cell body response of rubrospinal tract neurons	5431
the intrinsic cell body response	5431
rubrospinal tract neurons	5467
Tetzlaff	5494
et al. , 1991	5503
et al.	5503
1991	5511
Jenkins et al. , 1993	5517
Jenkins	5517
et al. , 1993	5525
et al.	5525
1993	5533
Kobayashi et al. , 1997	5539
Kobayashi	5539
et al. , 1997	5549
et al.	5549
1997	5557
Kwon et al. , 2002	5563
Kwon	5563
et al. , 2002	5568
et al.	5568
2002	5576
We	5583
dibutyryl cAMP	5602
dbcAMP	5618
the vicinity of the red nucleus	5644
the vicinity	5644
the red nucleus	5660
the axotomy-induced atrophy	5685
the expression of regeneration-associated genes , i.e. , GAP43 and Ta1-tubulin	5728
the expression	5728
regeneration-associated genes , i.e. , GAP43 and Ta1-tubulin	5746
regeneration-associated genes	5746
i.e.	5777
GAP43	5783
Ta1-tubulin	5793
we	5813
cAMP elevation	5839
the systemic level	5857
the cell body level of the red nucleus	5883
the cell body level	5883
the red nucleus	5906
regeneration of rubrospinal axons	5936
regeneration	5936
rubrospinal axons	5952
OEC transplants	5986
functional recovery of the forelimb following a cervical spinal cord injury	6021
functional recovery	6021
the forelimb following a cervical spinal cord injury	6044
the forelimb	6044
a cervical spinal cord injury	6067
this	6108
we	6114
transplant	6126
OECs	6140
the nasal mucosa of green fluorescent protein-expressing neonatal mouse	6158
the nasal mucosa	6158
green fluorescent protein-expressing neonatal mouse	6178
a systemic treatment	6235
a cell body treatment of the red nucleus elevating cAMP level for 2 weeks	6259
a cell body treatment	6259
the red nucleus elevating cAMP level for 2 weeks	6284
the red nucleus	6284
cAMP level for 2 weeks	6310
cAMP level	6310
2 weeks	6325
both combinatorial approaches	6343
regeneration of rubrospinal axons through and beyond engrafted OECs	6391
regeneration	6391
rubrospinal axons through and beyond engrafted OECs	6407
rubrospinal axons	6407
OECs	6454
the systemic elevation	6460
cAMP by rolipram infusion combined with OEC transplants	6486
cAMP	6486
rolipram infusion combined with OEC transplants	6494
rolipram infusion	6494
OEC transplants	6526
the numbers of OECs and axonal density	6552
the numbers	6552
OECs and axonal density	6567
OECs	6567
axonal density	6576
the graft	6598
motor recovery	6621
conjunction	6639
astrocytic hypertrophy rostral	6702
the lesion site	6736
MATERIALS AND METHODS Animal procedures	6754
MATERIALS	6754
METHODS Animal procedures	6768
accordance	6812
the guidelines of the Canadian Council for Animal Care	6828
the guidelines	6828
the Canadian Council for Animal Care	6846
the Canadian Council	6846
Animal Care	6871
the Animal Care Committee of the University of British Columbia	6904
the Animal Care Committee	6904
the University of British Columbia	6933
the University	6933
British Columbia	6951
Preparation of LP-OECs	6970
Preparation	6970
LP-OECs	6985
Green Fluorescent Protein Transgenic Mice	6998
The preparation of OECs	7040
The preparation	7040
OECs	7059
detailed elsewhere -LRB- Ramer et al. , 2004a ; Bretzner et al. , 2008 -RRB-	7086
detailed elsewhere	7086
detailed	7086
Ramer	7106
et al. , 2004a ; Bretzner et al. , 2008	7112
et al.	7112
2004a ; Bretzner et al.	7120
2004a	7120
Bretzner et al.	7127
Bretzner	7127
et al.	7136
2008	7144
brief	7154
postnatal day	7161
5 transgenic mice	7175
green fluorescent protein were sacrificed by decapitation	7204
green fluorescent protein	7204
decapitation	7249
the olfactory mucosa	7267
ice-cold DMEM/F12	7317
Au and Roskams , 2003 ; Ramer et al. , 2004a ; Richter et al. , 2005	7336
Au and Roskams	7336
Au	7336
Roskams	7343
2003 ; Ramer et al.	7352
2003	7352
Ramer et al.	7358
Ramer	7358
et al.	7364
2004a ; Richter et al. , 2005	7372
2004a	7372
Richter et al. , 2005	7379
Richter	7379
et al. , 2005	7387
et al.	7387
2005	7395
The entire olfactory mucosa , including turbinates and septum ,	7402
The entire olfactory mucosa	7402
turbinates and septum	7441
turbinates	7441
septum	7456
one pup	7483
0.6 mg/ml collagenase D -LRB- Roche Products , Indianapolis , IN -RRB-	7535
0.6 mg/ml collagenase D	7535
Roche Products , Indianapolis	7560
Roche Products	7560
Indianapolis	7576
50 µg/ml dispase I -LRB- Roche Products -RRB-	7595
50 µg/ml dispase I	7595
Roche Products	7615
15 lg/ml hyaluronidase -LRB- Sigma , St. Louis , MO -RRB-	7632
15 lg/ml hyaluronidase	7632
Sigma	7656
St. Louis	7663
MO	7674
0.5 mg/ml bovine serum albumin -LRB- MP Biomedicals , Irvine , CA -RRB-	7679
0.5 mg/ml bovine serum albumin	7679
MP Biomedicals	7711
Irvine	7727
CA	7735
200 U/ml DNase I	7744
200 U/ml DNase	7744
I	7759
Sigma	7762
1 hr	7773
378C	7781
centrifugation and plating	7794
Initial plating in MEM-D-valine	7822
Initial plating	7822
MEM-D-valine	7841
10 % fetal bovine serum -LRB- FBS -RRB-	7855
10 % fetal bovine serum	7855
FBS	7879
100 U/ml penicillin/streptomycin -LRB- P/S -RRB-	7889
100 U/ml penicillin/streptomycin	7889
P/S	7923
a poly L-lysine substrate	7933
additional mitogens	7967
4	8000
5 days	8002
purification enrichment performed using anti-Thy1.1-mediated complement lysis	8018
purification enrichment	8018
anti-Thy1.1-mediated complement lysis	8058
the majority of contaminating fibroblasts	8106
the majority	8106
contaminating fibroblasts	8122
Cells	8149
DMEM/F -12 , 10 % FBS , and 100 U/ml P/S	8172
DMEM/F -12	8172
10 % FBS	8183
100 U/ml P/S	8196
an additional 4	8233
6 days	8249
they	8271
Thy1.1-mediated complement lysis	8300
the same media for an additional 24	8346
the same media	8346
an additional 24	8365
48 hr	8382
transplantation	8397
a subset of cells	8428
a subset	8428
cells	8440
plastic coverslips	8462
antigenic assessment	8495
the same time	8519
cells	8547
the cultures for transplantation	8558
the cultures	8558
transplantation	8575
They	8592
as at least 75 % double immunopositive	8611
as at least 75 %	8611
p75 and GFAP	8653
the fibroblast portion -LRB- assessed as fibronectin1/p75 -- -RRB-	8670
the fibroblast portion	8670
fibronectin1/p75 --	8706
fibronectin1/p75	8706
25 %	8740
these culture conditions	8750
density of plating media , composition of plating media , and plating substrate	8776
density	8776
media , composition of plating media	8795
media	8795
composition of plating media	8802
composition	8802
plating media	8817
substrate	8844
we	8856
OECs	8887
Schwann cells	8916
Richter and Roskams	8950
2008	8971
This percentage	8978
that in our previous reports	9021
that	9021
our previous reports	9029
the results	9087
this study	9102
a 50 % fibroblast portion	9127
axonal regeneration	9202
Li	9223
et al. , 1997 , 1998 , 2003	9226
et al.	9226
1997	9234
1998	9240
2003	9246
The focus of this study	9253
The focus	9253
this study	9266
the effect of systemic and local cotreatments	9281
the effect	9281
systemic and local cotreatments	9295
the promotion of rubrospinal regeneration	9331
the promotion	9331
rubrospinal regeneration	9348
LP-OECs	9374
a density of 5,600 cells/cm2	9397
a density	9397
5,600 cells/cm2	9410
T75 flasks for transplantation	9431
T75 flasks	9431
transplantation	9446
transplantation	9470
the cells from one T75 flask of LP-OECs	9487
the cells	9487
one T75 flask of LP-OECs	9502
one T75 flask	9502
LP-OECs	9519
0.25 % trypsin/1 % EDTA	9547
0.25 %	9547
trypsin/1 %	9553
PBS	9593
resuspension at a concentration of 100,000 -- 120,000 cells/µl in DMEM/F -12	9601
resuspension at a concentration of 100,000	9601
resuspension	9601
a concentration of 100,000	9617
a concentration	9617
100,000	9636
120,000 cells/µl in DMEM/F -12	9644
120,000 cells/µl	9644
DMEM/F -12	9664
The total time from dissection to transplantation	9675
The total time	9675
dissection to transplantation	9695
dissection	9695
transplantation	9709
11 to 14 days	9737
initial experiments using freshly prepared OECs	9769
initial experiments	9769
freshly prepared OECs	9795
maintenance of phenotype	9827
maintenance	9827
phenotype	9842
cryopreservation	9858
cells -LRB- Ramer et al. , 2004a ; Bretzner et al. , 2008 -RRB-	9878
cells	9878
Ramer	9885
et al. , 2004a ; Bretzner et al. , 2008	9891
et al.	9891
2004a ; Bretzner et al.	9899
2004a	9899
Bretzner et al.	9906
Bretzner	9906
et al.	9915
2008	9923
we	9930
fresh OECs as well as cryopreserved cells	9938
fresh OECs	9938
cryopreserved cells	9960
the same batch in successive transplantations	9985
the same batch	9985
successive transplantations	10003
Spinal Cord Injury and Treatments	10032
Spinal Cord Injury	10032
Treatments	10055
total 47	10069
adult male Sprague-Dawley rats -LRB- 300 -- 400 g -RRB-	10078
adult male Sprague-Dawley rats	10078
300 -- 400 g	10110
300	10110
400 g	10114
this experiment	10135
Two groups from the current study -LRB- vehicle-DMEM and vehicle-OEC -RRB-	10152
Two groups	10152
the current study -LRB- vehicle-DMEM and vehicle-OEC -RRB-	10168
the current study	10168
vehicle-DMEM and vehicle-OEC	10187
vehicle-DMEM	10187
vehicle-OEC	10204
a study	10250
axonal regeneration and functional recovery	10268
axonal regeneration	10268
functional recovery	10292
OEC transplants in combination	10315
OEC transplants	10315
combination	10334
cell body treatment	10351
the red nucleus infusing BDNF -LRB- Bretzner et al. , 2008 -RRB-	10374
the red nucleus infusing BDNF	10374
Bretzner	10405
et al. , 2008	10414
et al.	10414
2008	10422
studies	10434
parallel	10460
identical conditions	10475
All rats	10497
cyclosporine A	10533
10 mg/kg	10549
day , i.p. ; Novartis Pharmaceuticals , Mississauga , Ontario , Canada	10562
day , i.p.	10562
day	10562
Novartis Pharmaceuticals , Mississauga , Ontario , Canada	10573
2 days	10629
surgery and each day	10643
surgery	10643
each day	10655
the duration of the experiment	10668
the duration	10668
the experiment	10684
Information Figure 1 and Table I	10715
Information Figure 1	10715
Information Figure	10715
1	10734
Table I	10740
Table	10740
I	10746
the experimental design and more details	10752
the experimental design	10752
more details	10780
We	10794
the treatment with cyclosporine A	10818
the treatment	10818
cyclosporine A	10837
cell death	10873
cyclosporine	10896
an inhibitor	10912
the mitochondrial permeability pore and neuroprotective	10928
the injured spinal cord -LRB- Halestrap et al. , 1997 -RRB-	10987
the injured spinal cord	10987
Halestrap	11012
et al. , 1997	11022
et al.	11022
1997	11030
we	11046
all groups	11057
this drug	11073
this effect	11084
unknown synergic effects with some of the treatments	11111
unknown synergic effects	11111
some of the treatments	11141
some	11141
the treatments	11149
Spinal cord injury .	11165
Spinal cord	11165
injury	11177
Dorsolateral funiculus	11185
Ramer et al. , 2004a ; Richter et al. , 2005 ; Bretzner et al. , 2008	11245
Ramer	11245
et al. , 2004a ; Richter et al. , 2005 ; Bretzner et al. , 2008	11251
et al. , 2004a	11251
et al.	11251
2004a	11259
Richter et al. , 2005	11266
Richter	11266
et al. , 2005	11274
et al.	11274
2005	11282
Bretzner et al. , 2008	11288
Bretzner	11288
et al. , 2008	11297
et al.	11297
2008	11305
Rats	11312
a mixture	11340
ketamine hydrochloride	11353
70 mg/kg , i.p. ; Bimeda-MTC , Cambridge , Ontario , Canada	11377
70 mg/kg , i.p.	11377
70 mg/kg	11377
Bimeda-MTC , Cambridge , Ontario , Canada	11393
xylazine hydrochloride	11437
10 mg/kg i.p. ; Bayer Inc. , Etobicoke , Ontario , Canada	11461
10 mg/kg i.p.	11461
10 mg/kg	11461
Bayer Inc. , Etobicoke , Ontario , Canada	11476
a laminectomy	11521
the left side	11552
the fourth and fifth cervical segments	11576
the fourth	11576
fifth cervical segments	11591
The dura	11616
microscissors	11638
the dorsolateral funiculus , which includes the rubrospinal tract	11662
the dorsolateral funiculus	11662
the rubrospinal tract	11705
The dorsolateral funiculus	11728
20 sec with a custom-designed fine surgical forceps	11771
20 sec	11771
a custom-designed fine surgical forceps	11783
a depth of 2 mm	11826
a depth	11826
2 mm	11837
the surface	11847
these forceps	11868
`` shoulders ''	11887
the blades	11914
a width of 0.2 mm and length of 2 mm	11928
a width of 0.2 mm	11928
a width	11928
0.2 mm	11939
length of 2 mm	11950
length	11950
2 mm	11960
it	11967
them	11992
a depth of 2 mm with good accuracy	12000
a depth	12000
2 mm with good accuracy	12011
2 mm	12011
good accuracy	12021
this dorsolateral funiculus crush lesion	12043
one animal	12114
another -LRB- Plunet et al. , 2008 -RRB-	12128
another	12128
Plunet	12137
et al. , 2008	12144
et al.	12144
2008	12152
us	12168
neuroanatomical changes	12182
spinal cord injury and the efficacy of various treatments	12216
spinal cord injury	12216
the efficacy of various treatments	12239
the efficacy	12239
various treatments	12255
Cell transplant .	12275
Cell	12275
transplant	12280
Lamina propria-derived OECs -LRB- LPOEC -RRB-	12292
Lamina propria-derived OECs	12292
LPOEC	12321
the spinal cord	12351
Ramer	12392
et al. , 2004a ; Richter et al. , 2005	12398
et al.	12398
2004a ; Richter et al.	12406
2004a	12406
Richter et al.	12413
Richter	12413
et al.	12421
2005	12429
LP-OEC slurries in DMEM/F -12	12436
LP-OEC slurries	12436
DMEM/F -12	12455
a pulled glass pipette with a diameter of 60	12481
a pulled glass pipette	12481
a diameter of 60	12509
a diameter	12509
60	12523
80 lm attached to a Hamilton syringe	12526
80 lm	12526
a Hamilton syringe	12544
OECs	12564
1 mm rostral and caudal	12604
1 mm rostral	12604
caudal	12621
the lesion site	12631
the suspension	12657
these two points	12688
A total of 1.5 µl of cell slurry	12706
A total	12706
1.5 µl of cell slurry	12717
1.5 µl	12717
cell slurry	12727
each rat	12761
a total of 150,000	12779
a total	12779
150,000	12790
180,000 cells	12798
Control animals	12813
the same volume of DMEM	12838
the same volume	12838
DMEM	12857
F-12	12863
the same sites	12880
the same rate	12898
The glass pipette	12913
place for 5 min	12943
place	12943
5 min	12953
each injection	12965
cells	12995
the spinal cord	13013
the syringe	13057
injection	13076
the pipette	13087
the muscle	13123
the skin	13152
wound clips	13173
Cell body treatment of the red nucleus infusing cAMP .	13186
Cell body treatment of the red nucleus	13186
Cell body treatment	13186
the red nucleus	13209
cAMP	13234
Dibutyryl cyclic adenosine monophosphate -LRB- dbcAMP -RRB- or vehicle	13240
Dibutyryl cyclic adenosine monophosphate -LRB- dbcAMP -RRB-	13240
Dibutyryl	13240
cyclic adenosine monophosphate -LRB- dbcAMP -RRB-	13250
cyclic adenosine monophosphate	13250
dbcAMP	13282
vehicle	13293
2 weeks	13317
a cannula	13329
the vicinity of the red nucleus	13363
the vicinity	13363
the red nucleus	13379
Kobayashi et al. , 1997 ; Kwon et al. , 2002 ; Bretzner et al. , 2008	13421
Kobayashi	13421
et al. , 1997 ; Kwon et al. , 2002 ; Bretzner et al. , 2008	13431
et al. , 1997	13431
et al.	13431
1997	13439
Kwon et al. , 2002	13445
Kwon	13445
et al. , 2002	13450
et al.	13450
2002	13458
Bretzner et al. , 2008	13464
Bretzner	13464
et al. , 2008	13473
et al.	13473
2008	13481
brief	13491
cell transplantation	13504
a 28-gauge cannula	13526
silastic tubing	13558
an osmotic minipump	13577
Alzet no. 2001 , 1 µl/hr ; Alzet , Palo Alto , CA	13598
Alzet no. 2001	13598
Alzet	13598
2001	13608
1 µl/hr ; Alzet	13614
1 µl/hr	13614
Alzet	13623
Palo Alto , CA	13630
Palo Alto	13630
CA	13641
stereotaxically 6.3 mm posterior	13658
6.3	13674
Bregma , 1.7 mm lateral -LRB- right -RRB- of midline	13694
Bregma	13694
1.7 mm lateral -LRB- right -RRB- of midline	13702
1.7 mm lateral -LRB- right -RRB-	13702
1.7 mm lateral	13702
right	13718
midline	13728
6.5 mm	13741
the dura	13758
Animals treated with cAMP	13768
Animals	13768
cAMP	13789
0.5 µg/µl/hr of cAMP -LRB- Calbiochem , La Jolla , CA -RRB-	13803
0.5 µg/µl/hr	13803
cAMP -LRB- Calbiochem , La Jolla , CA -RRB-	13819
cAMP	13819
Calbiochem	13825
La Jolla	13837
CA	13847
a vehicle solution of 20 mM sterile PBS and 100 units of penicillin/streptomycin	13854
a vehicle solution of 20 mM sterile PBS	13854
a vehicle solution	13854
20 mM sterile PBS	13876
20 mM	13876
100 units of penicillin/streptomycin	13898
100 units	13898
penicillin/streptomycin	13911
Animals treated with vehicle	13936
Animals	13936
vehicle	13957
the vehicle solution	13974
insertion	14008
the cannula and insertion of the miniosmotic pump under the skin of the neck	14021
the cannula and insertion	14021
the miniosmotic pump under the skin of the neck	14050
the miniosmotic pump	14050
the skin of the neck	14077
the skin	14077
the neck	14089
the skin	14099
wound clips	14124
Systemic treatment infusing rolipram .	14137
Systemic treatment	14137
rolipram	14165
Rolipram	14175
an inhibitor	14187
phosphodiesterase	14203
hydrolysis of cAMP	14235
hydrolysis	14235
cAMP	14249
accumulation of cAMP	14267
accumulation	14267
cAMP	14283
Rolipram or vehicle	14289
Rolipram	14289
vehicle	14301
the level of the left hindlimb	14339
the level	14339
the left hindlimb	14352
2 weeks	14374
a silicon tube	14386
an osmotic pump -LRB- Alzet no. 2ML1 , 10 µl/hr ; Alzet -RRB-	14414
an osmotic pump	14414
Alzet no. 2ML1 , 10 µl/hr ; Alzet	14431
Alzet no. 2ML1	14431
10 µl/hr ; Alzet	14447
10 µl/hr	14447
Alzet	14457
Pumps	14465
the end of each week	14487
the end	14487
each week	14498
the end of the 14 days	14523
the end	14523
the 14 days	14534
Animals treated with rolipram	14547
Animals	14547
rolipram	14568
0.4 µmol/kg/h of rolipram -LRB- Sigma -RRB-	14586
0.4 µmol/kg/h	14586
rolipram -LRB- Sigma -RRB-	14603
rolipram	14603
Sigma	14613
a vehicle solution of 20 mM sterile PBS and 16 % DMSO	14623
a vehicle solution	14623
20 mM sterile PBS and 16 % DMSO	14645
20 mM sterile PBS	14645
20 mM	14645
16 % DMSO	14667
Animals treated with vehicle	14677
Animals	14677
vehicle	14698
the vehicle solution	14715
insertion of the osmotic pump	14749
insertion	14749
the osmotic pump	14762
the skin	14780
wound clips	14805
Behavioral Testing Cylinder test .	14818
Behavioral Testing Cylinder	14818
test	14846
The forelimb usage	14852
a clear plexiglas cylinder -LRB- 20 cm in diameter and 30 cm high -RRB-	14889
a clear plexiglas cylinder	14889
20 cm in diameter and 30 cm	14917
20 cm	14917
diameter and 30 cm	14926
diameter	14926
30 cm	14939
5 min -LRB- Liu et al. , 1999 ; Schallert et al. , 2000 -RRB-	14955
5 min	14955
Liu	14962
et al. , 1999 ; Schallert et al. , 2000	14966
et al.	14966
1999 ; Schallert et al.	14974
1999	14974
Schallert et al.	14980
Schallert	14980
et al.	14990
2000	14998
The cylinder	15005
rats	15029
their forelimbs	15041
vertical exploration	15061
A mirror	15083
the cylinder	15110
scoring of movements from all viewpoints	15132
scoring	15132
movements from all viewpoints	15143
movements	15143
all viewpoints	15158
The behavior	15174
frame	15198
frame	15207
a later time point	15216
a blinded rater	15238
The forelimb use	15255
independent use of the left injured forelimb	15286
independent use	15286
the left injured forelimb	15305
independent use of the right forelimb	15332
independent use	15332
the right forelimb	15351
concomitant use of both forelimbs	15375
concomitant use	15375
both forelimbs	15394
the wall of the cylinder	15424
the wall	15424
the cylinder	15436
a full rear	15456
A minimum of 15 rears	15469
A minimum	15469
15 rears	15482
a more accurate use of the left forelimb	15512
a more accurate use	15512
the left forelimb	15535
the score	15554
a percentage use	15581
the `` left and both	15601
the `` left	15601
forelimbs relative to the total number of left , right , and both forelimb use	15623
forelimbs	15623
the total number of left , right , and both forelimb use	15645
the total number of left	15645
the total number	15645
both forelimb use	15682
Food-pellet-reaching task .	15701
The food-pellet-reaching task	15728
Whishaw 's test -LRB- Whishaw et al. , 1993 -RRB-	15775
Whishaw 's test	15775
Whishaw 's	15775
Whishaw	15791
et al. , 1993	15799
et al.	15799
1993	15807
the simplified	15818
Chan et al. , 2005	15865
Chan	15865
et al.	15870
2005	15878
brief	15888
the rats	15895
injury	15924
a 1-cm opening for a food pellet placed in a dimple 2 cm away	15948
a 1-cm opening	15948
a food pellet placed in a dimple 2 cm away	15967
a food pellet	15967
a dimple 2 cm away	15991
a dimple	15991
2 cm	16000
The animals	16011
the back of the box	16038
the back	16038
the box	16050
each reach and position itself for every reach	16064
each reach and position	16064
every reach	16099
The behavior	16112
a 10-point scale	16139
the execution of sequential aspects	16167
the execution	16167
sequential aspects	16184
score 3	16217
score 5	16237
score 7	16263
a food pellet	16272
details	16291
Chan	16303
et al. , 2005	16308
et al.	16308
2005	16316
the food-pellet-reaching task	16334
any influences	16379
other behavioral tests	16397
all rats	16421
week	16451
the night preceding the testing day	16459
the night	16459
the testing day	16479
Sensory tests	16496
Sensory testing	16511
rats	16549
allodynia	16570
the affected paw in a motor behavior test , e.g. , the cylinder test	16603
the affected paw	16603
a motor behavior test , e.g. , the cylinder test	16623
a motor behavior test	16623
e.g. , the cylinder test	16646
e.g.	16646
the cylinder test	16652
The sensory testing	16671
Ramer et al. , 2004b ; Bretzner et al. , 2008	16720
Ramer	16720
et al. , 2004b ; Bretzner et al. , 2008	16726
et al. , 2004b	16726
et al.	16726
2004b	16734
Bretzner et al. , 2008	16741
Bretzner	16741
et al. , 2008	16750
et al.	16750
2008	16758
The thermal threshold of forepaws	16765
The thermal threshold	16765
forepaws	16790
the plantar tester -LRB- Ugo Basile , Italy -RRB-	16821
the plantar tester	16821
Ugo Basile	16841
Italy	16853
Rats	16861
a raised cage with a wire mesh floor over a moveable infrared generator	16881
a raised cage	16881
a wire mesh floor over a moveable infrared generator	16900
a wire mesh floor	16900
a moveable infrared generator	16923
The infrared source	16954
The	16954
source	16967
the center of the palm of the forepaw	16995
the center	16995
the palm of the forepaw	17009
the palm	17009
the forepaw	17021
The time from stimulus onset to withdrawal	17034
The time	17034
stimulus onset to withdrawal	17048
stimulus onset	17048
withdrawal	17066
both forepaws	17094
The latency of withdraw	17109
The latency	17109
both forepaws	17150
Rats	17165
weekly two or three times for each paw	17182
weekly two or three times	17182
each paw	17212
2	17225
3 weeks before injury	17227
3 weeks	17227
injury	17242
a control baseline	17259
any training/adaptation effects	17294
the postinjury period	17333
4 weeks after injury and treatment	17368
4 weeks	17368
injury and treatment	17382
Baseline behavior	17404
surgery	17442
all animals	17455
4 weeks	17490
injury and treatment	17504
The observer	17526
the treatment given	17554
the treatment	17554
Rubrospinal Axons	17586
Immunocytochemistry Anterograde	17608
rubrospinal axons	17651
Five weeks	17670
spinal cord injury and treatment	17687
spinal cord injury	17687
treatment	17710
rats	17721
a mixture	17749
ketamine hydrochloride	17762
70 mg / kg , i.p. ; Bimeda-MTC	17786
70 mg / kg , i.p. ;	17786
70 mg	17786
kg	17793
Bimeda-MTC	17803
xylazine hydrochloride	17819
10 mg	17843
10	17843
mg	17846
kg i.p. ; Bayer Inc.	17850
kg i.p.	17850
kg	17850
Bayer Inc.	17859
Bayer	17859
Inc.	17865
a Kopf stereotaxic frame	17885
dextran amine	17924
BDA ; 10,000 kDa molecular mass	17939
BDA	17939
10,000 kDa molecular mass	17944
10,000 kDa	17944
molecular mass	17955
10 % in sterile water	17971
10 %	17971
sterile water	17978
Molecular Probes	17993
Eugene , OR	18011
Eugene	18011
OR	18019
the red nucleus	18057
a rate of 80 nl	18076
a rate	18076
80 nl	18086
min	18093
a pulled glass pipette -LRB- diameter of 20 µm -RRB- glued to a Hamilton syringe	18106
a pulled glass pipette -LRB- diameter of 20 µm -RRB-	18106
a pulled glass pipette	18106
diameter of 20 µm	18130
diameter	18130
20 µm	18142
a Hamilton syringe	18158
Coordinates	18178
6.1 mm posterior	18195
Bregma , 0.7 mm lateral -LRB- right -RRB- of midline	18215
Bregma	18215
0.7 mm lateral -LRB- right -RRB- of midline	18223
0.7 mm lateral -LRB- right -RRB-	18223
0.7 mm lateral	18223
right	18239
midline	18249
7 mm	18262
the dura	18277
The pipette	18287
place for 10 min	18311
place	18311
10 min	18321
injection	18334
BDA	18359
the syringe	18386
Immunohistochemistry .	18399
Six weeks	18421
injury and treatment	18437
rats	18459
a lethal dose of chloral hydrate	18487
a lethal dose	18487
chloral hydrate	18504
100 mg/kg , i.p. ; BDH Chemicals , Toronto , Ontario , Canada	18521
100 mg/kg , i.p. ; BDH Chemicals , Toronto , Ontario ,	18521
100 mg/kg , i.p.	18521
100 mg/kg	18521
BDH Chemicals , Toronto , Ontario ,	18538
BDH Chemicals	18538
Toronto , Ontario ,	18553
Canada	18571
PBS	18612
phosphate	18629
4 %	18648
paraformaldehyde -LRB- pH 7.4 -RRB-	18651
paraformaldehyde	18651
pH 7.4	18669
The midbrain , the cerebellum , and the cervical spinal cords	18678
The midbrain	18678
the cerebellum	18692
the cervical spinal cords	18712
4 % paraformaldehyde	18767
24 % sucrose in 0.1 M phosphate buffer over 2 -- 3 days	18815
24 % sucrose in 0.1 M phosphate buffer over 2	18815
24 % sucrose	18815
0.1 M phosphate buffer over 2	18830
0.1 M phosphate buffer	18830
2	18858
3 days	18860
isopentane over dry ice	18882
isopentane	18882
dry ice	18898
Spinal cord	18907
20-µm sections on a cryostat	18933
20-µm sections	18933
a cryostat	18951
2808C	18976
Cervical segments C2 and C7	18983
Cervical segments C2	18983
C7	19008
20-µm sections in the coronal plane	19025
20-µm sections	19025
the coronal plane	19043
Cervical segments from C3 to C6	19062
Cervical segments	19062
C3 to C6	19085
C3	19085
C6	19091
20-µm longitudinal sections in the horizontal plane	19108
20-µm longitudinal sections	19108
the horizontal plane	19139
frozen sections	19176
a slide warmer for 30 min	19207
a slide warmer	19207
30 min	19226
PBS 10 mM	19248
three times	19258
5 min each	19274
5 min	19274
each	19280
10 % normal donkey serum -LRB- in 0.1 % Triton X-100 -RRB-	19305
10 % normal donkey serum	19305
10 %	19305
in 0.1 % Triton X-100	19330
0.1 %	19333
Triton X-100	19338
Triton	19338
X-100	19345
30 min	19356
nonspecific binding	19374
The following primary antibodies	19395
chicken antigreen	19439
fluorescent protein -LRB- anti-GFP , 1:1,000 ; Chemicon , Termecula , CA -RRB-	19457
fluorescent protein	19457
anti-GFP , 1:1,000 ; Chemicon , Termecula , CA	19478
anti-GFP	19478
1:1,000 ; Chemicon	19488
1:1,000	19488
Chemicon	19497
Termecula , CA	19507
rabbit anti-GFP -LRB- anti-GFP , 1:1,000 ; Chemicon -RRB-	19523
rabbit anti-GFP	19523
anti-GFP , 1:1,000 ; Chemicon	19540
anti-GFP	19540
1:1,000 ; Chemicon	19550
1:1,000	19550
Chemicon	19559
mouse anti-GFAP -LRB- anti-GFAP , 1:400 ; Sigma -RRB-	19570
mouse anti-GFAP	19570
anti-GFAP , 1:400 ; Sigma	19587
anti-GFAP	19587
1:400 ; Sigma	19598
1:400	19598
Sigma	19605
mouse antineurofilament 200 -LRB- anti-NF , 1:400 ; Sigma -RRB-	19613
mouse antineurofilament	19613
200 -LRB- anti-NF , 1:400 ; Sigma -RRB-	19637
200	19637
anti-NF , 1:400 ; Sigma	19642
anti-NF	19642
1:400 ; Sigma	19651
1:400	19651
Sigma	19658
mouse anti-bIIItubulin	19666
anti-tub , 1:400 ; Sigma	19690
anti-tub	19690
1:400 ; Sigma	19700
1:400	19700
Sigma	19707
mouse anti-Ki67	19719
BD Biosciences	19736
Mississauga	19752
Ontario , Canada	19765
All primary antibodies	19783
24 hr at room temperature	19823
24 hr	19823
room temperature	19832
Secondary antibodies -LRB- 1:200 ; Jackson Immunoresearch -RRB-	19850
Secondary antibodies	19850
1:200 ; Jackson Immunoresearch	19872
1:200	19872
Jackson Immunoresearch	19879
donkey	19913
Alexa 350 , Alexa 488 , and Cy3	19935
Alexa 350	19935
Alexa 488	19946
Cy3	19961
2	19986
3 hr at room temperature	19988
3 hr	19988
room temperature	19996
BDA	20014
Cy3	20042
AMCA-conjugated streptavidin	20050
1:400 ; Jackson Immunoresearch	20080
1:400	20080
Jackson Immunoresearch	20087
West Grove , PA	20111
West Grove	20111
PA	20123
2	20139
3 hr at room temperature	20141
3 hr	20141
room temperature	20149
Sections	20167
glycerol mounting liquid -LRB- Sigma -RRB-	20197
glycerol mounting liquid	20197
Sigma	20223
In situ hybridization .	20231
In situ	20231
hybridization	20239
The protocol given by Verge et al. -LRB- 1992 -RRB-	20254
The protocol	20254
Verge	20276
et al.	20282
1992	20290
some modification	20311
The Ta1	20330
tubulin probe	20339
a 50-oligomer oligonucleotide	20357
the 30-untranslated sequence	20404
Ta1-tubulin 5AAACCCATCAGTGAAGTGGACGGCTCGGGTCTCTG ACAAATCATT CA-3	20436
the GAP-43 probe	20506
bases 220 -- 270 -LRB- Basi et al. , 1987 -RRB-	20544
bases 220 -- 270	20544
bases	20544
220 -- 270	20550
Basi	20559
et al. , 1987	20564
et al.	20564
1987	20572
These oligonucleotide probes	20579
35S-ATP	20630
deoxynucleotide terminal transferase	20644
a standard protocol	20694
GAP-43 and Ta1-tubulin ISH	20719
four sections from each animal	20747
four sections	20747
each animal	20766
that	20788
106 cpm of probe	20831
106 cpm	20831
probe	20842
16	20852
18 hr at 43 °C -LRB- for details see Giehl and Tetzlaff , 1996 -RRB-	20855
18 hr	20855
43 °C -LRB- for details see Giehl and Tetzlaff , 1996 -RRB-	20864
43 °C	20864
details	20874
Giehl and Tetzlaff , 1996	20886
Giehl and Tetzlaff	20886
1996	20906
The slides	20913
Kodak NTB-2 emulsion	20939
3 days for Ta1-tubulin and 7 days for GAP-43	20981
3 days for Ta1-tubulin	20981
3 days	20981
Ta1-tubulin	20992
7 days for GAP-43	21008
7 days	21008
GAP-43	21019
We	21027
GAP-43 and Ta1-tubulin probes	21045
GAP-43	21045
Ta1-tubulin probes	21056
a single band of the expected size in Northern blots of RNA	21080
a single band	21080
the expected size in Northern blots of RNA	21097
the expected size	21097
Northern blots of RNA	21118
Northern blots	21118
RNA	21136
facial nuclei	21145
identical or less stringent hybridization conditions	21165
Tetzlaff	21219
et al. , 1991	21228
et al.	21228
1991	21236
Sense-control probes	21243
no specific binding -LRB- data not shown -RRB-	21271
no specific binding	21271
data not shown	21292
data	21292
We	21309
essentially the same results	21321
GAP-43 and Ta1-tubulin ISH in no-pump control animals and our previous study	21354
GAP-43 and Ta1-tubulin ISH	21354
no-pump control animals and our previous study	21384
no-pump control animals	21384
our previous study	21412
cDNA probes of several hundred base pairs -LRB- Tetzlaff et al. , 1991 -RRB-	21437
cDNA probes	21437
several hundred base pairs -LRB- Tetzlaff et al. , 1991 -RRB-	21452
several hundred base pairs	21452
Tetzlaff	21480
et al. , 1991	21489
et al.	21489
1991	21497
the oligonucleotide probes in this study	21516
the oligonucleotide probes	21516
this study	21546
the low levels of GAP-43 and Ta1-tubulin	21566
the low levels	21566
GAP-43 and Ta1-tubulin	21584
the contralateral control rubrospinal neurons	21610
their higher sensitivity	21667
Image Analysis and Quantification Slides	21693
blind the observer	21748
images	21772
an Axioplan 2 microscope -LRB- Zeiss , Jena , Germany -RRB-	21808
an Axioplan 2 microscope	21808
Zeiss	21834
Jena	21841
Germany	21847
a digital camera -LRB- QImaging , Burnaby , British Columbia , Canada -RRB-	21857
a digital camera	21857
QImaging , Burnaby , British Columbia , Canada	21875
QImaging	21875
Burnaby	21885
British Columbia	21894
Canada	21912
Northern Eclipse software	21925
Empix Imaging	21952
Inc. , Mississauga	21967
Ontario , Canada	21986
Digital images	22004
Photoshop 7.0 -LRB- Adobe Systems , San Jose , CA -RRB-	22042
Photoshop 7.0	22042
Adobe Systems	22057
San Jose	22072
CA	22082
SigmaScan Pro -LRB- SPSS Inc. , Chicago , IL -RRB-	22087
SigmaScan	22087
Pro -LRB- SPSS Inc. , Chicago , IL -RRB-	22097
Pro	22097
SPSS Inc.	22102
Chicago	22113
IL	22122
Matlab 6.5 -LRB- The MathWorks , Inc. , Natick , MA -RRB- software	22131
Matlab 6.5 -LRB- The MathWorks , Inc. , Natick , MA -RRB-	22131
Matlab 6.5	22131
The MathWorks	22143
Inc.	22158
Natick , MA	22164
GFAP immunoreactivity	22186
the density	22235
a 50-µm-wide area	22254
the rim of the lesion site on three longitudinal sections	22278
the rim	22278
the lesion site on three longitudinal sections	22289
the lesion site	22289
three longitudinal sections	22308
animal	22341
the horizontal plane	22360
the dorsal root entry zone and the central canal	22409
the dorsal root entry zone	22409
the central canal	22440
This density value	22459
the value	22496
an analogous area on the contralateral uninjured side of the spinal cord	22520
an analogous area	22520
the contralateral uninjured side of the spinal cord	22541
the contralateral uninjured side	22541
the spinal cord	22577
Immunopositive cellular or axonal density measurements	22594
axonal density	22621
Ramer	22667
et al. -LRB- 2004b ;	22673
et al.	22673
2004b	22681
Fig. 2A	22692
Lesion area and cavity size	22702
Lesion area	22702
cavity size	22718
each animal	22750
the lesion area	22775
GFAP immunoreactivity	22802
three	22827
levels	22841
the dorsal root entry zone and the central canal	22876
the dorsal root entry zone	22876
the central canal	22907
the total pixels in this area -LRB- Fig. 2B -- D -RRB-	22941
the total pixels	22941
this area -LRB- Fig. 2B -- D -RRB-	22961
this area	22961
Fig. 2B -- D	22972
Fig. 2B	22972
D	22980
Measurements of OECs	22984
Measurements	22984
OECs	23000
Fig. 3	23026
Fig. 4 -RRB- through OEC transplants	23060
Fig.	23060
4 -RRB- through OEC transplants	23065
through	23068
transplants	23080
elsewhere -LRB- Ramer et al.	23120
elsewhere	23120
Ramer et al.	23131
Ramer	23131
et al.	23137
2001 , 2004b ; MacDermid et al.	23145
2001 , 2004b	23145
2001	23145
2004b	23151
et al.	23168
2004 ; Scott et al. , 2005	23176
2004	23176
Scott et al. , 2005	23182
Scott	23182
et al. , 2005	23188
et al.	23188
2005	23196
Bretzner et al. , 2008	23202
Bretzner	23202
et al. , 2008	23211
et al.	23211
2008	23219
The method	23226
Information Figure 7	23286
brief	23311
a Laplace	23318
the edges of the immunoreactive cellular or axonal profiles	23364
the edges	23364
the immunoreactive cellular or axonal profiles	23377
Info .	23431
7B	23442
This	23447
works	23462
an edge-detection filter	23471
all immunopositive processes	23509
their relative intensity	23552
These images	23578
overlays in which all pixels overlying immunopositive profiles had a value of 68	23625
overlays	23625
all pixels overlying immunopositive profiles	23643
all pixels	23643
immunopositive profiles	23664
a value of 68	23692
a value	23692
68	23703
all other pixels	23711
a value of 0	23732
a value	23732
0	23743
the resulting pixel values	23758
68	23788
a binary map of the image	23792
a binary map	23792
the image	23808
number of pixels	23837
number	23837
pixels	23847
function of the window area	23884
function	23884
the window area	23896
average intensity	23919
this manner	23944
density measurements -LRB- for examples	23969
density measurements	23969
examples	23995
Supp	24008
Info .	24014
Figs. 7C , 8 -RRB-	24020
Figs.	24020
7C , 8 -RRB-	24026
7C	24026
Three measurement windows	24034
the lesion epicenter	24083
either the rostral or the caudal edges	24107
the rostral	24114
the caudal edges	24129
the graft in order	24149
the graft	24149
order	24162
the number of pixels along this axis -LRB- Supp	24179
the number	24179
pixels along this axis -LRB- Supp	24193
pixels	24193
Supp	24217
Info .	24223
Fig.	24229
Cell profile density measurements	24239
these three measurement windows	24305
each side of the lesion , i.e. , rostral and caudal	24342
each side	24342
the lesion , i.e. , rostral and caudal	24355
the lesion	24355
i.e.	24367
rostral	24373
caudal	24385
three sections per animal	24413
three sections	24413
animal	24432
each treatment group	24459
a function	24507
the distance	24521
the lesion epicenter	24539
Info .	24567
Fig.	24573
The same procedure	24583
a measure	24624
OECs transplants -LRB- see Fig. 4 -RRB-	24666
OECs transplants	24666
Fig. 4	24688
the gray matter rostral	24729
the lesion	24756
Fig. 5C	24773
Cell density	24783
cell profile density in the rest of this paper	24819
cell profile density	24819
the rest of this paper	24843
the rest	24843
this paper	24855
we	24871
any changes in numbers	24890
any changes	24890
numbers	24905
changes in cell size	24918
changes	24918
cell size	24929
Rubrospinal regeneration	24940
the presence	24995
traced axons	25011
the spinal cord	25035
every other 20-µm section	25054
the longitudinal -LRB- horizontal -RRB- plane	25089
we	25153
any evidence for axonal regeneration	25169
any evidence	25169
axonal regeneration	25186
we	25207
each animal	25234
the distances	25246
the terminal ends	25268
the most caudal five rubrospinal axon tips and the lesion epicenter	25289
five rubrospinal axon tips and the lesion epicenter	25305
five rubrospinal axon tips	25305
the lesion epicenter	25336
the three best	25363
longitudinal sections of the rubrospinal tract	25385
longitudinal sections	25385
the rubrospinal tract	25410
the dorsolateral funiculus	25435
This	25463
a measure of rubrospinal axon retraction	25479
a measure	25479
rubrospinal axon retraction	25492
Fig. 5A , B	25525
Fig. 5A	25525
B	25533
addition to this	25540
addition	25540
this	25552
we	25558
the extent of rubrospinal branches/sprouts	25570
the extent	25570
rubrospinal branches/sprouts	25584
the gray matter on three different cervical coronal sections	25620
the gray matter	25620
three different cervical coronal sections	25639
C2	25684
These values	25688
the number	25720
rubrospinal axons	25734
the dorsolateral funiculus on three different cervical coronal sections	25768
the dorsolateral funiculus	25768
three different cervical coronal sections	25798
C2 -LRB- see Fig. 5C -RRB-	25843
C2	25843
Fig. 5C	25851
Statistical Analysis A two-way repeated ANOVA	25861
Statistical Analysis A two-way	25861
Statistical Analysis	25861
A two-way	25882
ANOVA	25901
interactions between treatment and distance	25926
interactions	25926
treatment and distance	25947
the axonal and cellular density	25974
interactions between treatment and time course	26020
interactions	26020
treatment and time course	26041
the behavioral outcomes	26071
A one-way ANOVA	26096
differences in the axonal or cellular density	26131
differences	26131
the axonal or cellular density	26146
each given distance	26180
differences in behavioral outcome measurements	26214
differences	26214
behavioral outcome measurements	26229
each time point	26264
A oneway ANOVA	26281
differences	26315
density measurements	26344
rubrospinal axon retraction and lesion area measurements	26376
the treatment	26446
The data	26461
further analyzed using the post hoc Tukey - Kramer test	26475
further	26475
the post hoc Tukey	26498
the post	26498
Kramer test	26518
the cases in which the variables did not fit a normal distribution	26534
the cases	26534
the variables	26553
a normal distribution	26579
the nonparametric Kruskal-Wallis	26602
sum test	26642
a x2 test	26673
all cases	26687
P values	26698
0.05 -LRB- two-tailed -RRB-	26708
0.05	26708
RESULTS	26756
I. Experimental Design *	26770
I. Experimental Design	26770
I.	26770
Experimental Design	26773
Different combinatorial therapies and the number of animal	26796
Different combinatorial therapies	26796
the number of animal	26834
the number	26834
animal	26848
histological and behavioral quantifications	26864
Histology	26909
Number	26920
the total number of animals used for histology	26937
the total number	26937
animals used for histology	26957
animals	26957
histology	26974
Numbers in parentheses	26985
Numbers	26985
parentheses	26996
the number	27012
animals	27026
BDA	27059
the dieback	27084
rubrospinal axons	27113
Fig. 1 .	27133
Fig.	27133
1	27138
Cell body treatment of the red nucleus infusing cAMP and OEC transplants	27141
Cell body treatment	27141
the red nucleus infusing cAMP and OEC transplants	27164
the red nucleus	27164
cAMP and OEC transplants	27189
regeneration of rubrospinal axons	27231
regeneration	27231
rubrospinal axons	27247
Rubrospinal axons -LRB- BDA in red -RRB- , LP-OECs -LRB- GFP in green -RRB-	27266
Rubrospinal axons	27266
BDA in red	27285
BDA	27285
red	27292
LP-OECs -LRB- GFP in green -RRB-	27298
LP-OECs	27298
GFP in green	27307
GFP	27307
glial scar -LRB- GFAP in blue -RRB- in typical longitudinal sections	27326
glial scar -LRB- GFAP in blue -RRB-	27326
glial scar	27326
GFAP in blue	27338
GFAP	27338
blue	27346
typical longitudinal sections	27355
the horizontal plane of spinal cords	27388
the horizontal plane	27388
spinal cords	27412
a vehicle-DMEM-treated rat	27430
A	27458
vehicle	27475
the rubrospinal neuron level and DMEM	27486
the rubrospinal neuron level	27486
DMEM	27519
the spinal cord level	27527
cAMP-DMEM-treated rat -LRB- B -RRB-	27550
cAMP-DMEM-treated rat	27550
B	27573
vehicle-OECs-treated rat -LRB- C -RRB-	27577
vehicle-OECs-treated rat	27577
C	27603
cAMP-OECs-treated rat -LRB- D -RRB-	27611
cAMP-OECs-treated rat	27611
D	27634
the lesion epicenter 310	27649
Scale	27675
5 250 µm	27685
-LSB- Color figure	27695
the online issue , which is available at wileyonlinelibrary.com	27726
the online issue	27726
wileyonlinelibrary.com	27766
Fig. 2 .	27792
Fig.	27792
2	27797
OECs	27800
the lesion	27810
cavity and glial scar formation	27832
A : GFAP immunodensity along the lesion site	27865
GFAP immunodensity along the lesion	27868
GFAP immunodensity	27868
the lesion	27893
the contralateral noninjured side	27923
B : Mean lesion area -LRB- GFAP negative area -RRB- .	27958
B	27958
Mean lesion area -LRB- GFAP negative area -RRB-	27961
Mean lesion area	27961
GFAP negative area	27979
C : Mean cavity formation area -LRB- area within the lesion site -RRB- .	28000
C	28000
Mean cavity formation area -LRB- area within the lesion site -RRB-	28003
Mean cavity formation area	28003
area within the lesion site	28031
area	28031
the lesion site	28043
D : Percentage of lesion site occupied by cavity .	28061
D	28061
Percentage of lesion site occupied by cavity	28064
Percentage	28064
lesion site	28078
cavity	28102
Error bars	28110
SEM	28130
one-way ANOVA	28135
Tukey-Kramer test for B	28161
Tukey-Kramer test	28161
B	28183
Kruskal-Wallis	28190
v2 test for A , C , D , * P < 0.05 compared with vehicle-DMEM	28217
v2 test for A , C , D , * P < 0.05	28217
v2 test	28217
A , C , D ,	28229
P <	28237
P	28237
<	28239
0.05	28241
vehicle-DMEM	28260
@P < 0.05 compared with vehicle	28274
@P	28274
vehicle	28298
DMEM and cAMP-DMEM	28307
DMEM	28307
cAMP-DMEM	28316
P < 0.05 compared with vehicle - DMEM and DMEM-rolipram	28328
P < 0.05 compared with vehicle	28328
P	28328
vehicle	28351
DMEM and DMEM-rolipram	28360
DMEM	28360
DMEM-rolipram	28369
Veh , vehicle ; Rolip , rolipram .	28385
Veh , vehicle	28385
Veh	28385
vehicle	28390
Rolip , rolipram	28399
Rolip	28399
rolipram	28406
Fig. 3 .	28417
Fig.	28417
3	28422
Systemic treatment with rolipram	28425
Systemic treatment	28425
rolipram	28449
the OEC density	28467
B : High-magnification images	28486
B	28486
High-magnification images	28489
typical longitudinal sections	28520
the horizontal plane of spinal cords	28553
the horizontal plane	28553
spinal cords	28577
vehicle-OEC-treated rats -LRB- A -RRB- and cAMP-OEC-treated rats -LRB- B -RRB-	28595
vehicle-OEC-treated rats	28595
A	28621
cAMP-OEC-treated rats	28628
B	28651
the Schwann cell-like morphology	28660
C	28694
OECs density throughout the graft in rats which received cell body treatment	28697
OECs density	28697
the graft in rats which received cell body treatment	28721
the graft	28721
rats which received cell body treatment	28734
rats	28734
cell body treatment	28754
D : Graft area in rats which received cell body treatment .	28775
D	28775
Graft area in rats which received cell body treatment	28778
Graft area	28778
rats which received cell body treatment	28792
rats	28792
cell body treatment	28812
E , F	28833
E	28833
F	28835
High-magnification images	28838
GFP-OECs	28867
GFP in green	28877
GFP	28877
axons	28895
NF200 and bIII-tubulin in red	28902
NF200 and bIII-tubulin	28902
red	28928
typical longitudinal sections	28938
the horizontal plane	28971
spinal cords	28995
vehicle-OEC-treated rats -LRB- E -RRB- and cAMP-OEC-treated rats -LRB- F -RRB-	29013
vehicle-OEC-treated rats	29013
E	29039
cAMP-OEC-treated rats	29046
F	29069
that OECs	29078
some thin and thick axons regardless of the treatment	29099
some thin and thick axons	29099
the treatment	29139
G	29154
L : Similar to A -- F in rats that received systemic treatment with rolipram	29156
L	29156
Similar to A -- F in rats that received systemic treatment with rolipram	29159
Similar	29159
A -- F in rats	29170
F in rats	29172
F	29172
rats	29177
systemic treatment	29196
rolipram	29220
One-way ANOVA	29230
Tukey-Kramer test or Kruskal-Wallis followed by x2 test	29256
Tukey-Kramer test or Kruskal-Wallis	29256
x2 test	29304
* P < 0.05 OEC-rolipram compared with OEC	29313
* P < 0.05 OEC-rolipram	29313
P <	29314
P	29314
<	29316
0.05 OEC-rolipram	29318
OEC	29350
Scale bars	29355
50 µm	29368
-LSB- Color figure	29375
the online issue , which is available at wileyonlinelibrary.com	29406
the online issue	29406
wileyonlinelibrary.com	29446
Fig. 4 .	29472
Fig.	29472
4	29477
Systemic treatment with rolipram	29480
Systemic treatment	29480
rolipram	29504
axonal density	29522
OEC transplants	29545
Typical longitudinal sections	29562
the horizontal plane of spinal cords	29595
the horizontal plane	29595
spinal cords	29619
vehicle-OEC-treated rats -LRB- A -RRB- and cAMP-OEC-treated rats -LRB- B -RRB-	29637
vehicle-OEC-treated rats	29637
A	29663
cAMP-OEC-treated rats	29670
B	29693
C	29697
Density	29700
thin and thick axons -LRB- NF200 - and bIII-tubulinpositive structures -RRB-	29711
thin and thick axons	29711
NF200	29733
bIII-tubulinpositive structures	29744
rats that received cell body treatment	29780
rats	29780
cell body treatment	29799
D	29820
F : Similar to A -- C in rats that received systemic treatment with rolipram	29822
F	29822
Similar to A -- C in rats that received systemic treatment with rolipram	29825
Similar	29825
A -- C in rats	29836
C in rats	29838
C	29838
rats	29843
systemic treatment	29862
rolipram	29886
One-way ANOVA	29896
Tukey-Kramer test or Kruskal-Wallis followed by v2 test	29922
Tukey-Kramer test or Kruskal-Wallis	29922
v2 test	29970
* P < 0.05 OEC-rolipram compared with OEC	29979
* P < 0.05 OEC-rolipram	29979
P <	29980
P	29980
<	29982
0.05 OEC-rolipram	29984
OEC	30016
Fig. 5 .	30022
Fig.	30022
5	30027
OEC transplants and cAMP elevation	30030
OEC transplants	30030
cAMP elevation	30050
regeneration	30081
retraction of rubrospinal tract axons	30106
retraction	30106
rubrospinal tract axons	30120
lesion epicenter	30149
A : Distance of rubrospinal axonal terminals from the lesion epicenter	30167
Distance of rubrospinal axonal terminals from the lesion epicenter	30170
Distance	30170
rubrospinal axonal terminals from the lesion epicenter	30182
rubrospinal axonal terminals	30182
the lesion epicenter	30216
a function of different treatments	30240
a function	30240
different treatments	30254
B	30276
Distance of rubrospinal axonal terminals from the lesion epicenter	30279
Distance	30279
rubrospinal axonal terminals from the lesion epicenter	30291
rubrospinal axonal terminals	30291
the lesion epicenter	30325
the number	30360
rubrospinal axons	30374
the dorsolateral funiculus at the cervical segment C2 rostral	30407
the dorsolateral funiculus	30407
the cervical segment C2 rostral	30437
the lesion	30472
C	30484
rubrospinal axon profile index at the cervical segment C2 rostral	30498
rubrospinal axon profile index	30498
the cervical segment C2 rostral	30532
the lesion site	30567
Error bars	30584
SEM	30604
one-way ANOVA	30609
Tukey-Kramer test for B	30635
Tukey-Kramer test	30635
B	30657
Kruskal-Wallis	30664
v2 test for A , C , * P < 0.05 compared with the control group vehicle - DMEM	30691
v2 test for A , C , * P < 0.05	30691
v2 test	30691
A , C ,	30703
C	30705
P <	30709
P	30709
<	30711
0.05	30713
the control group vehicle - DMEM	30732
Fig. 6 .	30767
Fig.	30767
6	30772
Thermal hypersensitivity resulting from OEC transplants .	30775
Thermal hypersensitivity	30775
OEC transplants	30815
Time courses	30832
the latency	30848
withdrawal reflexes	30863
thermal stimulation before and after spinal cord injury	30886
thermal stimulation	30886
spinal cord injury	30923
treatments in the left forepaw -LRB- top panels -RRB-	30946
treatments	30946
the left forepaw -LRB- top panels -RRB-	30960
the left forepaw	30960
top panels	30978
the right forepaw -LRB- bottom panels -RRB-	30997
the right forepaw	30997
bottom panels	31016
rats	31034
the cell body treatment -LRB- A , B -RRB- or the systemic treatment	31054
the cell body treatment	31054
A , B	31079
A	31079
B	31081
the systemic treatment	31087
Kruskal-Wallis	31117
x2 test	31144
P	31154
0.05 veh-OEC or OEC compared with veh-DMEM , + P <	31158
0.05 veh-OEC	31158
OEC compared with veh-DMEM , + P <	31174
OEC	31174
veh-DMEM , + P <	31192
veh-DMEM	31192
P <	31203
P	31203
0.05 OECrolipram compared with veh-DMEM , #dbcAMP compared with veh-DMEM , /	31207
0.05 OECrolipram	31207
veh-DMEM	31238
#dbcAMP	31248
veh-DMEM	31270
P <	31282
P	31282
0.05 OEC	31286
rolipram and OECrolipram	31309
Fig. 7 .	31336
Fig.	31336
7	31341
Systemic treatment infusing rolipram in combination with OEC transplants	31344
Systemic treatment infusing rolipram	31344
combination with OEC transplants	31384
combination	31384
OEC transplants	31401
the functional recovery of the left injured forelimb	31426
the functional recovery	31426
the left injured forelimb	31453
Time courses	31480
functional usage	31496
the left injured forelimb	31516
injury and treatments	31559
the cylinder test	31585
top panels	31604
the food-pellet-reaching task	31620
bottom panels	31651
rats	31669
the cell body treatment -LRB- A , B -RRB-	31688
the cell body treatment	31688
A , B	31713
A	31713
B	31715
the systemic treatment -LRB- C , D -RRB-	31721
the systemic treatment	31721
Kruskal-Wallis	31751
x2 test	31778
P	31788
0.05 OEC-rolipram compared with veh-DMEM	31792
0.05 OEC-rolipram	31792
veh-DMEM	31824
We	31835
rubrospinal axons	31865
transplants	31899
OECs	31914
the lamina propria -LRB- LP-OEC -RRB-	31932
the lamina propria	31932
LP-OEC	31952
the site	31980
a cervical dorsolateral funiculus crush -LRB- Ramer et al. , 2004a -RRB-	31992
a cervical dorsolateral funiculus crush	31992
Ramer	32033
et al. , 2004a	32039
et al.	32039
2004a	32047
there	32064
no evidence for regeneration of rubrospinal axons	32074
no evidence	32074
regeneration of rubrospinal axons	32090
regeneration	32090
rubrospinal axons	32106
the lesion site -LRB- Ramer et al. , 2004a -RRB-	32131
the lesion site	32131
Ramer	32148
et al. , 2004a	32154
et al.	32154
2004a	32162
the present study	32173
we	32192
the OECs	32208
we	32249
earlier studies	32265
this further reduced cavity formation	32286
glial scar formation at the lesion boundary	32328
glial scar formation	32328
the lesion boundary	32352
enhanced growth of neurofilament positive axons	32376
enhanced growth	32376
neurofilament positive axons	32395
the lesion site in comparison	32429
the lesion site	32429
comparison	32448
a direct transplantation	32464
the lesion -LRB- Richter et al. , 2005 -RRB-	32494
the lesion	32494
Richter	32506
et al. , 2005	32514
et al.	32514
2005	32522
the current study	32532
this improved transplantation strategy	32551
a 2-week elevation of dbcAMP	32608
a 2-week elevation	32608
dbcAMP	32630
the cell body of rubrospinal neurons via a direct infusion of dbcAMP	32647
the cell body	32647
rubrospinal neurons via a direct infusion of dbcAMP	32664
rubrospinal neurons	32664
a direct infusion of dbcAMP	32688
a direct infusion	32688
dbcAMP	32709
the systemic level via subcutaneous infusion	32722
the systemic level	32722
subcutaneous infusion	32745
rolipram	32770
the cAMP-degrading enzyme phosphodiesterase -LRB- isoform IV ;	32793
the cAMP-degrading enzyme phosphodiesterase	32793
isoform IV	32838
isoform	32838
IV	32846
experimental design	32854
Supp	32878
Info .	32884
Fig. 1 and Table I -RRB-	32890
Fig.	32890
1 and Table I -RRB-	32895
1	32895
Table I	32901
OECs	32911
the Lesion	32921
Cavity and Glial Scar Formation	32940
Align	32977
Axons	32988
We	32994
cAMP or rolipram	33018
the behavior of OECs	33043
the behavior	33043
OECs	33059
the injured spinal cord	33067
Injury of the dorsolateral funiculus in the rat	33092
Injury	33092
the dorsolateral funiculus in the rat	33102
the dorsolateral funiculus	33102
the rat	33132
the formation	33159
a cavity	33176
a rim of GFAPpositive hypertrophic astrocytes -LRB- Fig. 1A -RRB-	33199
a rim	33199
GFAPpositive hypertrophic astrocytes -LRB- Fig. 1A -RRB-	33208
GFAPpositive hypertrophic astrocytes	33208
Fig. 1A	33246
Examples of the treated spinal cords	33256
Examples	33256
the treated spinal cords	33268
Figure 1	33306
our previous reports -LRB- Ramer et al. , 2004a ; Richter et al. , 2005 -RRB-	33322
our previous reports	33322
Ramer	33344
et al. , 2004a ; Richter et al. , 2005	33350
et al.	33350
2004a ; Richter et al.	33358
2004a	33358
Richter et al.	33365
Richter	33365
et al.	33373
2005	33381
we	33388
three OEC transplant groups -LRB- Veh-OEC ; cAMP-OEC , and rolipram-OEC -RRB-	33402
three OEC transplant groups	33402
Veh-OEC ; cAMP-OEC , and rolipram-OEC	33431
Veh-OEC	33431
cAMP-OEC , and rolipram-OEC	33440
cAMP-OEC	33440
rolipram-OEC	33454
the GFAP immunoreactivity	33480
the lesion edge	33513
a reduced astrocytic activation -LRB- Fig. 2A -RRB-	33543
a reduced astrocytic activation	33543
Fig. 2A	33576
OECs	33586
the lesion site	33628
many OECs interdigitating with the host environment	33650
many OECs	33650
the host environment	33681
The demarcation by reactive astrocytes -LRB- GFAPpositive lesion boundary -RRB-	33703
The demarcation by reactive astrocytes	33703
The demarcation	33703
reactive astrocytes	33722
GFAPpositive lesion boundary	33743
the lesion area -LRB- defined by a disrupted spinal cord cytoarchitecture -RRB-	33793
the lesion area	33793
a disrupted spinal cord cytoarchitecture	33821
a	33821
spinal cord cytoarchitecture	33833
All OEC treatment groups	33864
combination with cAMP-increasing strategies	33902
combination	33902
cAMP-increasing strategies	33919
the size of the lesion area -LRB- Fig. 2B -RRB-	33966
the size	33966
the lesion area -LRB- Fig. 2B -RRB-	33978
the lesion area	33978
Fig. 2B	33995
most of the lesion site	34021
most	34021
the lesion site	34029
they	34046
only a small fraction	34056
the lesion occupied by cavity -LRB- Figs. 1C , D , 2C , D -RRB-	34081
the lesion	34081
cavity -LRB- Figs. 1C , D , 2C , D -RRB-	34104
cavity	34104
Figs. 1C	34112
D , 2C , D	34121
this reduction of the lesion area by OECs	34140
this reduction	34140
the lesion area by OECs	34158
the lesion area	34158
OECs	34177
significance	34196
the direct comparison of the veh-DMEM control group	34212
the direct comparison	34212
the veh-DMEM control group	34237
the other OEC-treated groups	34269
Fig. 2B ; P = 0.07 for veh-OEC ; P = 0.11 for cAMP-OEC ; P = 0.11 for OEC	34299
Fig. 2B	34299
P = 0.07 for veh-OEC ; P = 0.11 for cAMP-OEC ; P = 0.11 for OEC	34308
P = 0.07 for veh-OEC	34308
P = 0.07	34308
P	34308
0.07	34312
veh-OEC	34321
P = 0.11 for cAMP-OEC	34330
P = 0.11	34330
P	34330
0.11	34334
cAMP-OEC	34343
P = 0.11 for OEC	34353
P = 0.11	34353
P	34353
0.11	34357
OEC	34366
P = 0.33 for rolip-OEC groups	34371
P = 0.33	34371
P	34371
0.33	34375
rolip-OEC groups	34384
the combination of OECs with either cAMP-elevating strategy	34414
the combination	34414
OECs	34433
cAMP-elevating strategy	34450
the trend of the OECs	34498
the trend	34498
the OECs	34511
lesion area -LRB- Fig. 2B -RRB-	34530
lesion area	34530
Fig. 2B	34543
an increase in graft size	34561
an increase	34561
graft size	34576
the size	34605
the lesion area -LRB- i.e. , disrupted spinal cord cytoarchitecture -RRB-	34617
the lesion area	34617
i.e. , disrupted spinal cord cytoarchitecture	34634
i.e.	34634
spinal cord cytoarchitecture	34650
we	34681
the OEC graft size	34695
cross-sectional area of the GFP positive cells	34726
cross-sectional area	34726
the GFP positive cells	34750
rolipram treatment	34780
a strong trend	34809
increased graft size	34831
from 3.64 ± 1.1 to 5.5 ± 0.63 SEM , P = 0.07 , Student 's t-test ; Fig. 3J	34853
3.64	34858
± 1.1 to 5.5 ± 0.63 SEM , P = 0.07 , Student 's t-test ; Fig. 3J	34863
± 1.1 to 5.5 ± 0.63 SEM , P = 0.07 , Student 's t-test	34863
± 1.1 to 5.5 ± 0.63 SEM	34863
P = 0.07	34888
P	34888
0.07	34892
Student 's t-test	34898
Student 's	34898
Fig. 3J	34916
Fig.	34916
3J	34921
The density	34926
GFP-positive cells	34941
the two injection sites	34968
1.5 mm rostral to 1.5 mm caudal to the injury	34998
1.5 mm rostral	34998
1.5 mm caudal to the injury	35016
1.5 mm caudal	35016
the injury	35033
the systemic rolipram-treatment group -LRB- Fig. 3I -RRB-	35073
the systemic rolipram-treatment group	35073
Fig. 3I	35112
An increase in density of the GFP1 OECs	35122
An increase	35122
density of the GFP1 OECs	35137
density	35137
the GFP1 OECs	35148
cell body treatment with dbcAMP -LRB- Fig. 3C -RRB-	35181
cell body treatment	35181
dbcAMP -LRB- Fig. 3C -RRB-	35206
dbcAMP	35206
Fig. 3C	35214
this increased OEC density in the systemic rolipram-treatment group	35232
this increased OEC density	35232
the systemic rolipram-treatment group	35262
no cellular proliferation	35301
the end of the experimental period	35343
the end	35343
the experimental period	35354
Ki67 immunostaining -LRB- Supp	35381
Ki67	35381
immunostaining -LRB- Supp	35386
Info .	35408
Fig.	35414
5 ; see	35419
5	35419
Discussion for further details	35426
Discussion	35426
further details	35441
The majority of the transplanted OECs	35459
The majority	35459
the transplanted OECs	35475
a spindle-shaped	35501
morphology	35529
the cell body or systemic treatments -LRB- top panels in Fig. 3 -RRB-	35554
the cell body	35554
systemic treatments -LRB- top panels in Fig. 3 -RRB-	35571
systemic treatments	35571
top panels in Fig. 3	35592
top panels	35592
Fig. 3	35606
Most OECs	35615
cellular strands that had a random orientation in the lesion epicenter	35641
cellular strands	35641
a random orientation in the lesion epicenter	35667
a random orientation	35667
the lesion epicenter	35691
rostrocaudal orientation	35728
the host white matter with finger-like processes	35758
the host white matter	35758
finger-like processes	35785
Double immunostaining for axonal profiles	35808
Double immunostaining	35808
axonal profiles	35834
these strands	35864
axonal profiles of all calibers -LRB- bottom panels in Fig. 3 -RRB-	35896
axonal profiles	35896
all calibers -LRB- bottom panels in Fig. 3 -RRB-	35915
all calibers	35915
bottom panels in Fig. 3	35929
bottom panels	35929
Fig. 3	35946
addition	35958
we	35968
OECs	35998
large numbers of host Schwann cells	36011
large numbers	36011
host Schwann cells	36028
newly forming blood vessels	36052
these strands	36085
much	36108
the GFP-negative spaces in these transplants -LRB- Ramer et al. , 2004a -RRB-	36116
the GFP-negative spaces	36116
these transplants -LRB- Ramer et al. , 2004a -RRB-	36143
these transplants	36143
Ramer	36162
et al. , 2004a	36168
et al.	36168
2004a	36176
Axonal Regeneration We	36184
the regeneration/sprouting of axons	36221
the regeneration/sprouting	36221
axons	36251
these LP-OEC-filled lesion sites	36270
various axonal populations	36313
we	36341
antibodies	36349
both neurofilament 200 and bIII-tubulin	36364
both neurofilament 200	36364
bIII-tubulin	36391
their density	36419
the OEC-filled lesion site	36440
Fig. 4A , D	36468
Fig. 4A	36468
D	36476
The systemic treatment with rolipram	36480
The systemic treatment	36480
rolipram	36508
the axonal density	36541
the lesion site -LRB- Fig. 4D -- F -RRB-	36567
the lesion site	36567
Fig. 4D -- F	36584
Fig. 4D	36584
F	36592
the localized cell body treatment of the red nucleus with dbcAMP	36604
the localized cell body treatment	36604
the red nucleus with dbcAMP	36641
the red nucleus	36641
dbcAMP	36662
no significant effects on the density of axonal sprouts -LRB- Fig. 4A -- C -RRB-	36673
no significant effects	36673
the density of axonal sprouts -LRB- Fig. 4A -- C -RRB-	36699
the density	36699
axonal sprouts -LRB- Fig. 4A -- C -RRB-	36714
axonal sprouts	36714
Fig. 4A -- C	36730
Fig. 4A	36730
C	36738
levels of GAP-43 and Ta1-tubulin mRNA expression	36751
levels	36751
GAP-43 and Ta1-tubulin mRNA expression	36761
injured rubrospinal neurons	36818
local infusion of dbcAMP in our preliminary studies	36851
local infusion	36851
dbcAMP in our preliminary studies	36869
dbcAMP	36869
our preliminary studies	36879
Supp	36904
Info .	36910
Fig. 3	36916
Fig.	36916
3	36921
this absence of an effect	36925
this absence	36925
an effect	36941
overall axonal density	36954
any effect on rubrospinal axons	37007
any effect	37007
rubrospinal axons	37021
a cell body treatment	37042
the many other axons of various origins	37091
the many other axons	37091
various origins	37115
the lesion site that also stain for neurofilament 200 and bIII-tubulin	37138
the lesion site	37138
neurofilament 200 and bIII-tubulin	37174
neurofilament 200	37174
bIII-tubulin	37196
We	37210
the sprouting/regeneration	37235
anterogradely traced rubrospinal axons into / through this spinal bridge of OECs	37265
anterogradely	37265
rubrospinal axons	37286
this spinal bridge	37318
OECs	37340
any rubrospinal axon growth	37366
the lesion in any treatment group	37401
the lesion	37401
any treatment group	37415
some rubrospinal axons	37445
close association with rostral OEC grafts	37476
close association	37476
rostral OEC grafts	37499
they	37519
engrafted OEC transplants bridging the lesion site itself	37550
engrafted OEC transplants	37550
the lesion site	37585
itself	37601
in Figure 1C and in our camera lucida drawings	37618
Figure 1C	37621
our camera lucida	37638
Info .	37672
4	37683
neither cell body treatment	37698
the red nucleus with dbcAMP nor systemic treatment with rolipram	37729
the red nucleus	37729
dbcAMP nor systemic treatment with rolipram	37750
dbcAMP	37750
systemic treatment with rolipram	37761
systemic treatment	37761
rolipram	37785
regeneration of rubrospinal axons	37803
regeneration	37803
rubrospinal axons	37819
the OEC transplants -LRB- Fig. 1D , Supp	37845
the OEC transplants	37845
Fig. 1D	37866
Supp	37875
Info .	37881
2C , 4	37893
2C	37893
4	37897
there	37910
pronounced differences in the morphology of the rubrospinal tract rostral	37921
pronounced differences	37921
the morphology of the rubrospinal tract rostral	37947
the morphology	37947
the rubrospinal tract rostral	37965
the site of injury	37998
the site	37998
injury	38010
Rubrospinal axons	38018
axotomy -LRB- Ye and Houle , 1997 -RRB-	38064
axotomy	38064
Ye and Houle , 1997	38073
Ye	38073
Houle , 1997	38080
Houle	38080
1997	38087
we	38098
their dystrophic endings	38107
1,700 µm -LRB- 6323 µm -RRB-	38141
6323 µm	38151
rostral	38160
the lesion epicenter in our control condition	38173
the lesion epicenter	38173
our control condition	38197
DMEM in Fig. 1A	38225
DMEM	38225
Fig. 1A	38233
Supp	38245
Info .	38251
Fig. 4 ; Bretzner et al. , 2008 -RRB- .	38257
Fig. 4	38257
Bretzner et al. , 2008 -RRB-	38265
Bretzner	38265
et al.	38274
2008	38282
This retraction of rubrospinal axons	38289
This retraction	38289
rubrospinal axons	38308
all treatment groups	38358
veh-DMEM -LRB- Fig. 5A , Supp	38393
veh-DMEM	38393
Fig. 5A	38403
Supp	38412
Info .	38418
4	38429
It	38433
most anterogradely traced axons	38462
most	38462
axons	38488
the host tissue	38507
proximity	38558
the transplanted OECs	38573
the injections sites -LRB- Fig. 1D , Supp	38603
the injections sites	38603
Fig. 1D	38625
Supp	38634
Info .	38640
2C , 4	38652
2C	38652
4	38656
The straight course of many of these axons	38660
The straight course	38660
many of these axons	38683
many	38683
these axons	38691
the interpretation	38712
these axons	38736
it	38775
retracting axons	38807
newly sprouted and subsequently frustrated axons	38843
These group differences in rubrospinal axon profiles at the rostral lesion edge	38893
These group differences	38893
rubrospinal axon profiles at the rostral lesion edge	38920
rubrospinal axon profiles	38920
the rostral lesion edge	38949
differences	38989
the efficacy	39004
anterograde	39020
there	39052
no significant differences	39063
the number of traced rubrospinal axons at the C2 level of the spinal cord	39093
the number	39093
traced rubrospinal axons at the C2 level of the spinal cord	39107
traced rubrospinal axons	39107
the C2 level of the spinal cord	39135
the C2 level	39135
the spinal cord	39151
data not shown	39168
data	39168
We	39185
the possibility	39202
our treatment	39223
the terminal branching of the RS axons within the cervical gray matter	39257
the terminal branching of the RS axons	39257
the RS	39283
the cervical gray matter	39303
It	39329
rubrospinal axons	39352
spinal interneurons that bypass the lesion site and thereby contribute	39389
spinal interneurons	39389
the lesion site	39421
functional recovery	39463
corticospinal axons -LRB- Bareyre et al. , 2004 ; Vavrek et al. , 2006 -RRB-	39517
corticospinal axons	39517
Bareyre	39538
et al. , 2004 ; Vavrek et al. , 2006	39546
et al.	39546
2004 ; Vavrek et al.	39554
2004	39554
Vavrek et al.	39560
Vavrek	39560
et al.	39567
2006	39575
the density of rubrospinal axon profiles	39589
the density	39589
rubrospinal axon profiles	39604
the gray matter on cervical cross-sections	39650
the gray matter	39650
cervical cross-sections	39669
C2 -LRB- i.e. , more than a segment rostral to the lesion -RRB-	39696
C2	39696
a segment rostral to the lesion	39716
a segment rostral	39716
the lesion	39737
the number	39767
cross-sectioned axons	39789
the rubrospinal tract	39814
this level	39839
axon profile index ; Fig. 5C	39862
axon profile index	39862
Fig. 5C	39882
There	39892
no significant change in axon profiles	39902
no significant change	39902
axon profiles	39927
any treatment group	39944
the OEC-rolipram group	39974
significantly more branches	40004
the rolipram-DMEM treatment group	40037
a direct paired t-test -LRB- P < 0.006 -RRB-	40074
a direct paired t-test	40074
P < 0.006	40098
P	40098
< 0.006	40100
<	40100
0.006	40102
Functional Outcomes To understand the behavioral effects of our treatments	40110
Functional Outcomes	40110
the behavioral effects of our treatments	40144
the behavioral effects	40144
our treatments	40170
we	40186
the sensory thresholds	40196
thermal and mechanical stimulations of the forepaws -LRB- Fig. 6 , Supp	40222
thermal and mechanical stimulations	40222
the forepaws -LRB- Fig. 6 , Supp	40261
the forepaws	40261
Fig. 6	40275
Supp	40283
Info .	40289
6	40300
response to thermal stimulation	40307
response	40307
thermal stimulation	40319
the withdrawal latency in the left forepaw -LRB- side of injury -RRB-	40340
the withdrawal latency	40340
the left forepaw -LRB- side of injury -RRB-	40366
the left forepaw	40366
side of injury	40384
side	40384
injury	40392
all experimental groups	40424
the veh-DMEM controls -LRB- top panels in Fig. 6 -RRB-	40462
the veh-DMEM controls	40462
top panels in Fig. 6	40485
top panels	40485
Fig. 6	40499
Shorter withdrawal latencies	40508
significance	40545
the OEC	40566
OEC-rolipram groups -LRB- weeks 3 and 4 , respectively ; Fig. 6C -RRB-	40578
OEC-rolipram groups	40578
weeks 3 and 4 , respectively ; Fig. 6C	40599
weeks 3 and 4 , respectively	40599
weeks 3 and 4	40599
Fig. 6C	40628
the contralateral right forepaw	40652
veh-OEC and OEC transplants	40685
the withdrawal latency	40730
treatment scenarios	40763
bottom panels in Fig. 6	40784
bottom panels	40784
Fig. 6	40801
these observations	40819
transplantation of OECs	40851
transplantation	40851
OECs	40870
thermal hypersensitivity of the forepaws	40890
thermal hypersensitivity	40890
the forepaws	40918
We	40932
the mechanical thresholds	40949
no significant changes	40985
the cell body treatment with cAMP	41032
the cell body treatment	41032
cAMP	41061
Info .	41073
6	41084
technical reasons	41107
we	41126
changes for the systemic treatment	41158
changes	41158
the systemic treatment	41170
We	41194
the performance of the left injured forelimb	41211
the performance	41211
the left injured forelimb	41230
the cylinder test -LRB- top panels in Fig. 7 -RRB-	41259
the cylinder test	41259
top panels in Fig. 7	41278
top panels	41278
Fig. 7	41292
the food-pellet-reaching task -LRB- bottom panels in Fig. 7 -RRB-	41311
the food-pellet-reaching task	41311
bottom panels in Fig. 7	41342
bottom panels	41342
Fig. 7	41359
the cylinder test , before dorsolateral funiculus lesion	41371
the cylinder test	41371
dorsolateral funiculus lesion	41397
all animals	41428
75 % of the time with the `` left and both ''	41453
75 %	41453
the time with the `` left and both ''	41460
the time	41460
the `` left and both	41474
the `` left	41474
forelimbs during vertical exploration -LRB- Liu et al. , 1999 -RRB-	41496
forelimbs	41496
vertical exploration	41513
Liu	41535
et al. , 1999	41539
et al.	41539
1999	41547
spinal cord injury	41560
the usage of the left plus both forelimbs for the control group	41580
the usage of the left	41580
the usage	41580
the left	41593
both forelimbs for the control group	41607
both forelimbs	41607
the control group	41626
vehicle-DMEM	41645
30 -- 40 %	41670
30	41670
baseline	41699
the 4 weeks of assessment	41713
the 4 weeks	41713
assessment	41728
all individual treatments as well as the dbcAMP-OEC combination	41749
all individual treatments	41749
all	41749
individual treatments	41753
the dbcAMP-OEC combination	41786
a usage of left	41825
a usage	41825
left	41836
both forelimbs of about 50 %	41846
both forelimbs	41846
50 %	41870
only the combination of OEC transplant with systemic infusion of rolipram	41875
only the combination	41875
OEC transplant with systemic infusion of rolipram	41899
OEC transplant	41899
systemic infusion of rolipram	41919
systemic infusion	41919
rolipram	41940
significance	41957
a usage level of 59 %	41973
a usage level	41973
59 %	41990
There	41995
no significant differences	42006
therapies in the food - pellet-reaching task -LRB- bottom panels in Fig. 7 -RRB-	42041
therapies	42041
the food - pellet-reaching task -LRB- bottom panels in Fig. 7 -RRB-	42054
the food	42054
pellet-reaching task	42064
bottom panels in Fig. 7	42086
bottom panels	42086
Fig. 7	42103
summary	42115
OEC transplants	42133
the thermal hypersensitivity of the forepaws	42159
the thermal hypersensitivity	42159
the forepaws	42191
their combination with systemic infusion of rolipram	42205
their combination	42205
systemic infusion of rolipram	42228
systemic infusion	42228
rolipram	42249
the return of usage of the left injured forelimb	42267
the return	42267
usage of the left injured forelimb	42281
usage	42281
the left injured forelimb	42290
vertical exploration in a cylinder	42323
vertical exploration	42323
a cylinder	42347
Correlations	42359
Anatomical and Behavioral Measurements	42380
most studies of the injured spinal cord	42427
most studies	42427
the injured spinal cord	42443
we	42468
the mechanisms	42493
anatomical parameters	42517
the improvement of functional recovery	42553
the improvement	42553
functional recovery	42572
we	42599
correlation analyses of forelimb usage , improved by rolipram plus OECs ,	42612
correlation analyses	42612
forelimb usage , improved by rolipram plus OECs ,	42636
forelimb usage	42636
rolipram plus OECs	42664
rolipram	42664
OECs	42678
our anatomical measurements	42689
This	42718
any causality	42738
possible links	42765
example	42785
GFAP expression	42802
better transplant integration	42835
more axons to cross the transplant -- host interface	42882
the transplant -- host interface	42902
the transplant	42902
host interface	42917
We	42933
a significant inverse correlation	42942
the percentage of usage of the left forelimb	42984
the percentage	42984
usage of the left forelimb	43002
usage	43002
the left forelimb	43011
vertical exploration in the cylinder test	43036
vertical exploration	43036
the cylinder test	43060
the immunoreactivity for GFAP -LRB- R < 20.35 , P < 0.03 -RRB-	43082
the immunoreactivity	43082
GFAP -LRB- R < 20.35 , P < 0.03 -RRB-	43107
GFAP	43107
R < 20.35	43113
R	43113
< 20.35	43115
<	43115
20.35	43117
P < 0.03	43124
P	43124
< 0.03	43126
<	43126
0.03	43128
i.e.	43135
rats using their left forelimb more	43141
rats	43141
their	43152
less GFAP immunoreactivity	43198
addition	43229
there	43239
a correlation	43249
the percentage of usage of the left forelimb in the cylinder test	43271
the percentage	43271
usage of the left forelimb in the cylinder test	43289
usage	43289
the left forelimb in the cylinder test	43298
the left forelimb	43298
the cylinder test	43319
the branching	43342
rubrospinal axons rostral	43359
the lesion site in the animals treated with OECs and rolipram	43388
the lesion site	43388
the animals treated with OECs and rolipram	43407
the animals	43407
OECs and rolipram	43432
R < 0.76	43451
R	43451
< 0.76	43453
<	43453
0.76	43455
P < 0.078	43461
P	43461
< 0.078	43463
<	43463
0.078	43465
DISCUSSION	43474
we	43490
our previous work -LRB- Ramer et al. , 2004a ; Richter et al. , 2005 -RRB-	43519
our previous work	43519
Ramer	43538
et al. , 2004a ; Richter et al. , 2005	43544
et al.	43544
2004a ; Richter et al.	43552
2004a	43552
Richter et al.	43559
Richter	43559
et al.	43567
2005	43575
neonatal mouse lamina	43582
the injured rat spinal cord	43641
the lesion site	43677
cavitation	43704
the host astrocytic hypertrophy	43731
massive	43780
the injury site	43810
Transplantation	43827
OECs with or without dbcAMP to the red nucleus or systemic rolipram	43846
OECs	43846
dbcAMP to the red nucleus or systemic rolipram	43867
dbcAMP	43867
the red nucleus or systemic rolipram	43877
the red nucleus	43877
systemic rolipram	43896
the axonal dieback of rubrospinal axons	43922
the axonal dieback	43922
rubrospinal axons	43944
their regeneration	43984
the injury site	44019
rolipram treatment	44041
the density of the transplanted OECs	44069
the density	44069
the transplanted OECs	44084
the density of axonal sprouting into the OEC transplants	44125
the density	44125
axonal sprouting into the OEC transplants	44140
axonal	44140
the OEC transplants	44162
The combined treatment group of OECs with rolipram	44183
The combined treatment group	44183
OECs with rolipram	44215
OECs	44215
rolipram	44225
significant recovery of forelimb usage	44241
significant recovery	44241
forelimb usage	44265
a cylinder test	44283
the levels of controls	44322
the levels	44322
controls	44336
this functional improvement	44356
an	44404
astrocytic hypertrophy and an enhanced rubrospinal branching rotral	44418
astrocytic hypertrophy	44418
an enhanced rubrospinal branching rotral	44445
the lesion site	44489
this latter combination group as well as OECs alone	44520
this latter combination group	44520
OECs alone	44561
OECs	44561
lowered thermal thresholds	44582
sensory testing of the forepaw	44614
sensory testing	44614
the forepaw	44633
the side of injury	44648
the side	44648
injury	44660
thermal allodynia	44682
Two treatments	44701
the aim of increasing cAMP	44733
the aim	44733
increasing cAMP	44744
the level of the red nucleus by dbcAMP infusion	44779
the level	44779
the red nucleus by dbcAMP infusion	44792
the red nucleus	44792
dbcAMP infusion	44811
rolipram , a phosphodiesterase inhibitor ,	44848
rolipram	44848
a phosphodiesterase inhibitor	44858
osmotic minipumps	44916
Infusion of dbcAMP	44935
Infusion	44935
dbcAMP	44947
the retraction of rubrospinal axons	44971
the retraction	44971
rubrospinal axons	44989
the injury site	45012
the effect	45043
any of the other histopathological parameters at the lesion site	45057
any	45057
the other histopathological parameters at the lesion site	45064
the other histopathological parameters	45064
the lesion site	45106
behavior	45136
significance	45159
It	45173
the prevention of retraction/dieback	45204
the prevention	45204
retraction/dieback	45222
axons	45259
both	45277
parallel	45295
the straight course and larger caliber of many of these axons	45314
the straight course	45314
larger caliber of many of these axons	45338
larger caliber	45338
many of these axons	45356
many	45356
these axons	45364
these	45389
This	45415
the dbcAMP treatment of the rubrospinal neurons	45435
the dbcAMP treatment	45435
the rubrospinal neurons	45459
a neuroprotective effect on their axons	45487
a neuroprotective effect	45487
their axons	45515
Several specific downstream effectors	45528
cAMP treatment	45593
dorsal root ganglion cells	45611
a positive role	45648
axonal growth	45667
Cai et al. , 1999 ; Neumann et al. , 2002 ; Qiu et al. , 2002	45682
Cai	45682
et al. , 1999 ; Neumann et al. , 2002 ; Qiu et al. , 2002	45686
et al. , 1999	45686
et al.	45686
1999	45694
Neumann et al. , 2002	45700
Neumann	45700
et al. , 2002	45708
et al.	45708
2002	45716
Qiu et al. , 2002	45722
Qiu	45722
et al. , 2002	45726
et al.	45726
2002	45734
we	45752
increased levels of GAP-43 and Ta1-tubulin mRNA expression	45761
increased levels	45761
GAP-43 and Ta1-tubulin mRNA expression	45781
injured rubrospinal neurons	45823
local infusion of dbcAMP -LRB- Supp	45856
local infusion	45856
dbcAMP -LRB- Supp	45874
Info .	45888
3	45899
It	45903
these latter regeneration-associated gene products	45923
the maintainance of the axonal stumps	45993
the maintainance	45993
the axonal stumps	46013
their regeneration	46041
The local infusion of dbcAMP near the rubrospinal cell bodies	46081
The local infusion	46081
dbcAMP near the rubrospinal cell bodies	46103
dbcAMP	46103
the rubrospinal cell bodies	46115
some inflammation and tissue damage	46162
the infusion site	46205
a translational perspective	46232
a proof of principle	46278
a proof	46278
principle	46289
Local tissue damage by dbcAMP	46300
Local tissue damage	46300
dbcAMP	46323
others -LRB- Lu and Richardson , 1991 ; Fouad et al. , 2009 -RRB-	46360
others	46360
Lu and Richardson	46368
Lu	46368
Richardson	46375
1991 ; Fouad et al. , 2009	46387
1991	46387
Fouad et al. , 2009	46393
Fouad	46393
et al. , 2009	46399
et al.	46399
2009	46407
It	46414
the systemic treatment with rolipram , a clinically used drug ,	46453
the systemic treatment	46453
rolipram , a clinically used drug ,	46481
rolipram	46481
a clinically used drug	46491
rubrospinal axon retraction	46536
combination with OEC transplantation	46568
combination	46568
OEC transplantation	46585
rolipram treatment	46606
several beneficial effects	46629
any of the other treatment groups	46669
any	46669
the other treatment groups	46676
these	46704
the density of the OECs	46733
the density	46733
the OECs	46748
the transplants	46760
increasing axonal density in the lesion	46780
increasing axonal density	46780
the lesion	46809
motor recovery of forelimb usage	46824
motor recovery	46824
forelimb usage	46842
we	46867
survival	46889
ongoing proliferative effects of rolipram -LRB- Alexander et al. , 2002 -RRB-	46903
ongoing proliferative effects	46903
rolipram -LRB- Alexander et al. , 2002 -RRB-	46936
rolipram	46936
Alexander	46946
et al. , 2002	46956
et al.	46956
2002	46964
we	46971
no evidence	46980
any proliferation	46996
the end	47017
the experimental period	47028
by Ki67 immunostaining	47063
Info .	47093
5	47104
a cAMP elevation	47127
GFAP expression	47177
OECs	47196
their morphology	47215
an astrocyte-like type within 1 day	47235
an astrocyte-like type	47235
1 day	47265
Doucette and Devon , 1995 ; Vincent et al. , 2003	47281
Doucette and Devon	47281
1995 ; Vincent et al.	47301
1995	47301
Vincent et al.	47307
Vincent	47307
et al.	47315
2003	47323
our transplanted OECs	47330
an elongated , spindle-shape morphology	47362
an	47362
spindle-shape morphology	47376
GFAP levels	47421
immunohistochemistry at the end of the experimental period in the current study	47447
immunohistochemistry	47447
the end of the experimental period in the current study	47471
the end	47471
the experimental period in the current study	47482
the experimental period	47482
the current study	47509
rolipram	47537
this time	47571
we	47585
a proliferative effect of rolipram	47606
a proliferative effect	47606
rolipram	47632
some changes in OECs morphology and transient GFAP expression	47652
some changes	47652
OECs morphology and transient GFAP expression	47668
OECs morphology	47668
transient GFAP expression	47688
the earlier treatment stage	47717
a higher OEC density in the transplants	47759
a higher OEC density	47759
the transplants	47783
the amount of trophic factors produced	47819
the amount	47819
trophic factors produced	47833
trophic factors	47833
olfactory bulb-derived OECs	47863
a source	47913
trophic factors	47925
Boruch	47942
et al. , 2001	47949
et al.	47949
2001	47957
Lipson et al. , 2003	47963
Lipson	47963
et al. , 2003	47970
et al.	47970
2003	47978
Sasaki et al. , 2006b	47984
Sasaki	47984
et al. , 2006b	47991
et al.	47991
2006b	47999
Wang et al. , 2006	48006
Wang	48006
et al. , 2006	48011
et al.	48011
2006	48019
This in turn	48026
This	48026
turn	48034
stronger effects on the host	48053
stronger effects	48053
the host	48073
spinal cord	48082
trophic factors	48101
axonal sprouting and sparing -LRB- Hendriks et al. , 2006 -RRB-	48125
axonal sprouting and sparing	48125
axonal	48125
Hendriks	48155
et al. , 2006	48164
et al.	48164
2006	48172
cellular excitability	48190
the absence of rubrospinal axonal regeneration	48224
the absence	48224
rubrospinal axonal regeneration	48239
the systemic combinatorial therapy with OEC-rolipram	48272
the systemic combinatorial therapy	48272
OEC-rolipram	48312
recovery of left forelimb usage	48334
recovery	48334
left forelimb usage	48346
this	48371
astrocytic hypertrophy	48403
rubrospinal axons rostral	48452
the lesion site	48481
It	48498
these enhanced branches of rubrospinal axons	48518
these enhanced branches	48518
rubrospinal axons	48545
spinal interneuronal networks	48574
the lesion in the spared host tissue	48618
the lesion	48618
the spared host tissue	48632
Examples for such mechanisms	48656
Examples	48656
such mechanisms	48669
the injured corticospinal system	48711
Bareyre	48745
et al. , 2004 ; Vavrek et al. , 2006	48753
et al.	48753
2004 ; Vavrek et al.	48761
2004	48761
Vavrek et al.	48767
Vavrek	48767
et al.	48774
2006	48782
the intact rubrospinal system	48806
pyramidal tract injury and IN-1 antibody treatment	48855
Raineteau	48907
et al. , 2002	48917
et al.	48917
2002	48925
such	48945
the recovery	48992
limb usage	49008
mainly proximal limb muscles innervated from higher cervical spinal cord levels	49035
mainly proximal limb muscles	49035
higher cervical spinal cord levels	49080
they	49120
distal limb muscles	49144
the lower spinal cord levels	49187
there	49228
no recovery in the food-pellet-reaching test	49238
no recovery	49238
the food-pellet-reaching test	49253
contrast to dorsal root ganglia -LRB- Qiu et al. , 2002 ; Lu et al. , 2004 -RRB-	49287
contrast	49287
dorsal root ganglia -LRB- Qiu et al. , 2002 ; Lu et al. , 2004 -RRB-	49299
dorsal root ganglia	49299
Qiu	49320
et al. , 2002 ; Lu et al. , 2004	49324
et al.	49324
2002 ; Lu et al.	49332
2002	49332
Lu et al.	49338
Lu	49338
et al.	49341
2004	49349
cell body treatment of the red nucleus	49356
cell body treatment	49356
the red nucleus	49379
axonal regeneration of rubrospinal neurons	49413
axonal regeneration	49413
rubrospinal neurons	49436
cell transplants	49461
these last neurons	49500
axotomy than dorsal root ganglia	49548
axotomy	49548
dorsal root ganglia	49561
the absence	49593
regeneration of rubrospinal tract axons into OECs grafts with either treatments	49608
regeneration	49608
rubrospinal tract axons into OECs grafts with either treatments	49624
rubrospinal tract axons	49624
OECs grafts	49653
treatments	49677
contrast to our earlier results	49698
contrast	49698
our earlier results	49710
peripheral nerve grafts -LRB- Kobayashi et al. , 1997 -RRB-	49735
peripheral nerve grafts	49735
Kobayashi	49760
et al. , 1997	49770
et al.	49770
1997	49778
This	49785
rubrospinal axons	49804
OECs grafts	49845
the OEC	49869
grafts	49877
critical factors or spatial alignments	49889
critical factors	49889
spatial alignments	49909
nerve grafts	49942
Transplant-induced plasticity	49956
other host	49999
axonal systems as well , which we left untraced , including the sensory systems	50010
axonal systems	50010
we	50040
the sensory systems	50068
Our sensory measurements	50089
the OECs	50127
a tendency to lower thermal thresholds	50146
a tendency	50146
lower thermal thresholds	50160
this effect	50190
the combination of OECs	50219
the combination	50219
OECs	50238
rolipram	50248
This effect	50258
a higher level of neurotrophins in the injured spinal cord	50286
a higher level	50286
neurotrophins in the injured spinal cord	50304
neurotrophins	50304
the injured spinal cord	50321
neurotrophins such as NGF and BDNF	50346
neurotrophins	50346
NGF and BDNF	50368
the sensitization	50417
dorsal horn neurons	50438
the spinal cord	50461
Kerr et al. , 1999 ; Mannion et al. , 1999 ; Heppenstall and Lewin , 2001	50478
Kerr	50478
et al. , 1999 ; Mannion et al. , 1999 ; Heppenstall and Lewin , 2001	50483
et al. , 1999	50483
et al.	50483
1999	50491
Mannion et al. , 1999	50497
Mannion	50497
et al. , 1999	50505
et al.	50505
1999	50513
Heppenstall and Lewin , 2001	50519
Heppenstall and Lewin	50519
2001	50542
Olfactory bulb-derived OECs	50549
the mRNAs for these neurotrophins	50585
the mRNAs	50585
these neurotrophins	50599
the proteins	50632
Boruch	50646
et al. , 2001	50653
et al.	50653
2001	50661
Lipson et al. , 2003	50667
Lipson	50667
et al. , 2003	50674
et al.	50674
2003	50682
Sasaki et al. , 2006b	50688
Sasaki	50688
et al. , 2006b	50695
et al.	50695
2006b	50703
Wang et al. , 2006	50710
Wang	50710
et al. , 2006	50715
et al.	50715
2006	50723
Schwann cells	50741
the spinal cord	50760
neurotrophin levels	50794
the lesion site -LRB- Sasaki et al. , 2006b -RRB-	50828
the lesion site	50828
Sasaki	50845
et al. , 2006b	50852
et al.	50852
2006b	50860
similar direct or indirect trophic effects	50881
similar direct	50881
indirect trophic effects	50899
LP-OECs	50945
we	50958
their ability to attract endogenous Schwann cells previously	50975
endogenous Schwann cells	51000
Ramer	51037
et al. , 2004a	51043
et al.	51043
2004a	51051
addition	51062
rolipram	51072
the release of glutamate	51096
the release	51096
glutamate	51111
the nerve terminals -LRB- Wang , 2006 -RRB-	51124
the nerve terminals	51124
Wang	51145
2006	51151
this sensitization of sensory neurons	51186
this sensitization	51186
sensory neurons	51208
this	51234
an enhanced release of glutamate by rubrospinal and other axonal terminals	51255
an enhanced release	51255
glutamate by rubrospinal and other axonal terminals	51278
glutamate	51278
rubrospinal and other axonal terminals	51291
the excitability of spinal interneuronal circuits	51351
the excitability	51351
spinal interneuronal circuits	51371
only the combination of OEC with rolipram	51409
only the combination	51409
OEC with rolipram	51433
OEC	51433
rolipram	51442
the motor performance	51460
the cylinder test	51485
this	51508
the rubrospinal branching rostral to the lesion site	51540
the rubrospinal branching rostral	51540
the lesion site	51577
summary	51597
thermal hypersensitivity resulting from the lamina propria-derived OECs	51614
thermal hypersensitivity	51614
the lamina propria-derived OECs	51654
the possibility	51687
autologous cell transplants	51712
combination with systemic rolipram infusion	51743
combination	51743
systemic rolipram infusion	51760
regard	51811
the motor recovery	51821
the enhanced engrafted cells survival/division	51841
the axonal regeneration/sprouting into the transplant	51889
the axonal regeneration/sprouting	51889
the transplant	51928
the potential functional sprouting / sparing of rubrospinal tract axons rostral	51948
sparing of rubrospinal tract axons	51984
sparing	51984
rubrospinal tract axons	51995
the lesion	52030
the future	52045
we	52056
more	52098
the neural mechanisms	52116
this functional recovery	52154
some alternatives	52188
the thermal hypersensitivity	52216
OEC transplants	52260
their ability	52293
clinical trials	52310
